Patent Grant
11771821
The disclosure relates generally to the field of infusion systems for medicaments and components thereof.
Sustained delivery, pump driven medicament injection devices generally include a delivery cannula mounted in a subcutaneous manner through the skin of the patient at an infusion site. The pump draws medicine from a reservoir and delivers it to the patient via the cannula. The injection device typically includes a channel that transmits a medicament from an inlet port to the delivery cannula which results in delivery to the subcutaneous tissue layer where the delivery cannula terminates. Some infusion devices are configured to deliver one medicament to a patient while others are configured to deliver multiple medicaments to patient.
Some embodiments disclosed herein pertain to medicament infusion systems, components thereof, and methods of using and/or making infusion systems.
In some embodiments, a medicament infusion set for delivering a single or multiple medicaments to a patient is disclosed. In some embodiments, the medicament infusion set comprises a first reservoir set. In some embodiments, the first reservoir set comprises a first reservoir comprising a first reservoir port that contains a first medicament. In some embodiments, the first reservoir set comprises a first inlet connector that fits over at least a portion of the first reservoir and at least a portion of the first reservoir port. In some embodiments, the first inlet connector comprises a first needle configured to allow access to the first medicament. In some embodiments, the first inlet connector comprises a first engaging member that engages a portion of the first reservoir attaching the first inlet connector to the first reservoir.
Any of the embodiments described above, or described elsewhere herein, can include one or more of the following features.
In some embodiments, the first inlet connector comprises a first check valve. In some embodiments, the check valve is configured to allow fluid to flow from the first reservoir in response to a first threshold fluid pressure.
In some embodiments, the first inlet connector comprises a cover configured to engage the first inlet connector.
In some embodiments, the medicament infusion set further comprises a second reservoir set. In some embodiments, the second reservoir set comprises a second reservoir comprising a second reservoir port that allows access to a second medicament.
In some embodiments, the second reservoir set comprises a second inlet connector that fits over at least a portion of the second reservoir and at least a portion of the second port. In some embodiments, the second inlet connector comprises a second needle configured to allow access a second medicament. In some embodiments, the second inlet connector comprises a second engaging member that engages a portion of the second reservoir attaching the second inlet connector to the second reservoir.
In some embodiments, the second reservoir set comprises a second inlet connector cover configured to engage the second inlet connector.
In some embodiments, the first check valve is configured to substantially prevent unintended leaking of the first medicament from the first reservoir.
In some embodiments, the second inlet connector comprises a second check valve configured to allow fluid flow from the second reservoir in response to a second threshold pressure being reached.
Some embodiments pertain to a medicament infusion set for delivering a single or multiple medicaments to a patient. In some embodiments, the medicament infusion set comprises a first reservoir set.
In some embodiments, the first reservoir set comprises a first reservoir comprising a first reservoir port and a first plunger. In some embodiments, the first reservoir contains a first medicament. In some embodiments, the first plunger comprises a first insert. In some embodiments, the insert comprises a magnetic material distributed throughout the first insert. In some embodiments, the first insert is configured to magnetically couple to a drive nut in a pump that is configured to deliver the first medicament.
In some embodiments, the first reservoir set comprises a first inlet connector. In some embodiments, the first inlet connector fits over at least a portion of the first reservoir and at least a portion of the first reservoir port. In some embodiments, the first inlet connector comprises a first needle configured to allow access to the first medicament. In some embodiments, the first inlet connector comprises a first engaging member that engages a portion of the first reservoir attaching the first inlet connector to the first reservoir.
In some embodiments, the first reservoir set comprises a first inlet connector cover configured to engage the first inlet connector.
In some embodiments, the first insert is rubber, plastic, polymeric, elastomeric, or combinations thereof.
In some embodiments, the medicament infusion set further comprises a second reservoir set comprising a second reservoir comprising a second reservoir port configured to allow access to a second medicament.
In some embodiments, the second reservoir set comprises a second inlet connector that fits over at least a portion of the second reservoir and at least a portion of the second port. In some embodiments, the second inlet connector comprises a second needle configured to allow access a second medicament. In some embodiments, the second inlet connector comprises a second engaging member that engages a portion of the second reservoir attaching the second inlet connector to the second reservoir.
In some embodiments, the medicament infusion set comprises a second inlet connector cover configured to engage the second inlet connector.
In some embodiments, the magnetic material is a material selected from the group consisting of ferrous material, metal shavings, metal beads, and/or metal powder.
In some embodiments, the magnetic material is configured to magnetically couple the first plunger and a magnet at a terminal end of a drive nut of a pump in a way that prevents inadvertent lift-off of the plunger from the drive nut.
In some embodiments, the second reservoir comprises a second plunger comprising a second insert, the second insert comprising a second magnetic material distributed throughout the second insert, wherein the second insert is configured to magnetically repel the first drive nut and to attract a second drive nut of the pump.
In some embodiments, the infusion set comprises the pump.
Some embodiments pertain to a medicament infusion system comprising a pump and a first medicament reservoir. In some embodiments, the pump comprises one or more of a first reservoir receptacle, a motor, and a drive nut located within the first reservoir receptacle and configured to move a plunger to deliver medicament in response to a first electrical current applied to the motor. In some embodiments, the pump comprises a controller. In some embodiment the controller is configured to urge the drive nut forward with the first electrical current. In some embodiments, the first electrical current is insufficient to advance the drive nut forward when in contact with the first plunger. In some embodiments, the controller (and/or a detector of the pump) is configured to detect whether the plunger corresponds to the first plunger. In some embodiments, in response to the detection that the plunger corresponds to the first plunger, the controller is configured to increase an electrical current applied to the motor to a delivery mode current that is sufficient to urge the drive nut forward against the plunger and to move the plunger to deliver the first medicament. In some embodiments, in response to the detection that the plunger does not correspond to the first plunger, the controller is configured to reduce the electrical current applied to the motor or apply a second electrical current that retracts the drive nut.
Some embodiments pertain to a medicament infusion system comprising a pump and a controller. In some embodiments, the medicament infusion system further comprises a first medicament reservoir with a first plunger and a first medicament. In some embodiments, the first medicament reservoir comprises a first plunger and a first medicament. In some embodiments, the pump comprises a first medicament reservoir receptacle configured to hold a medicament reservoir. In some embodiments, the pump comprises a motor. In some embodiments, the pump comprises a drive nut located within the first reservoir receptacle and configured to move in response to a first electrical current applied to the motor. In some embodiments, the pump comprises the controller.
In some embodiments, the controller is configured to apply the first electrical current to the drive nut. In some embodiments, the controller urges the drive nut forward with the first electrical current. In some embodiments, the first electrical current is insufficient to advance the drive nut forward when in contact with a plunger of a medicament reservoir. In some embodiments, in response to the detection of the first plunger, the controller increases an electrical current applied to the motor to a delivery mode current that is sufficient to urge the drive nut forward against the first plunger and to move the first plunger to deliver the first medicament.
In some embodiments, the controller is configured to detect whether the plunger corresponds to the first plunger and, in response to the detection that the plunger does not correspond to the first plunger, the controller reduces the electrical current applied to the motor and/or applies a second electrical current that retracts the drive nut when a plunger that is not the first plunger is detected. In some embodiments, the controller is configured to probe whether the plunger corresponds to the first plunger by tapping against the plunger with successively increased force by increasing the electrical current incrementally from the first electrical current until the force is sufficient to cause the plunger moves thereby indicating the presence of the first plunger (e.g., because the force required to move the plunger corresponds to that required to move the first plunger).
Some embodiments pertain to a controller for controlling operations of a medicament infusion system. In some embodiments, the controller is configured to apply a first electrical current that is configured to advance a drive nut forward. In some embodiments, the first electrical current is less than a threshold current needed to advance the drive nut forward when the drive nut is in contact with a plunger. In some embodiments, in response to the detection that the plunger corresponds to the first type of plunger, the controller increases the first electrical current to a delivery mode current that is sufficient to advance the drive nut forward against the plunger and to move the plunger to deliver a first medicament. In some embodiments, the controller is further configured to interact with a detector. In some embodiments, the detector detects whether the plunger corresponds to a first type of plunger. In some embodiments, in response to the detection that the plunger does not correspond to the first type of plunger, the controller applies a second electrical current to the drive nut that retracts the drive nut or decreases the current to stop the drive nut completely. In some embodiments, the controller is configured to probe whether the plunger corresponds to the first plunger by tapping against the plunger with successively increased force by increasing the electrical current incrementally from the first electrical current until the force is sufficient to cause the plunger moves thereby indicating the presence of the first plunger.
Some embodiments pertain to a medicament infusion set for delivering a single or multiple medicaments to a patient, comprising a first reservoir set. In some embodiments, the first reservoir set comprises a first reservoir comprising a first reservoir port and a first plunger. In some embodiments, the first reservoir comprises a first medicament.
In some embodiments, the first plunger comprises an electrically conducting element configured to interact with an infusion pump such that when the first reservoir is properly positioned in the infusion pump the first plunger is in electronic communication with the infusion pump.
In some embodiments, the first inlet connector that fits over at least a portion of the first reservoir and at least a portion of the first reservoir port.
In some embodiments, the first inlet connector comprises a first needle configured to allow access to the first medicament.
In some embodiments, the first inlet connector comprises a first engaging member that engages a portion of the first reservoir attaching the first inlet connector to the first reservoir.
In some embodiments, the first reservoir set comprises a first inlet connector cover configured to engage the first inlet connector.
In some embodiments, the medicament infusion set further comprises a second reservoir set comprising a second reservoir comprising a second reservoir port configured to allow access to a second medicament within the reservoir.
In some embodiments, the second reservoir set comprises a second inlet connector that fits over at least a portion of the second reservoir and at least a portion of the second port.
In some embodiments, the second inlet connector comprises a second needle configured to allow access a second medicament.
In some embodiments, the second inlet connector comprises a second engaging member that engages a portion of the second reservoir attaching the second inlet connector to the second reservoir.
In some embodiments, the second reservoir set comprises a second inlet connector cover configured to engage the second inlet connector.
In some embodiments, the second reservoir comprises a second plunger wherein the second plunger comprises an electrically conducting element configured to interact with the infusion pump such that when the second reservoir is properly positioned in the infusion pump the second plunger is in electronic communication with the infusion pump.
In some embodiments, the first plunger comprises a first insert comprising a magnetic material distributed throughout the first insert, wherein the first insert is configured to magnetically couple to the first drive nut in the pump.
In some embodiments, the first inlet connector comprises a first check valve that allows fluid flow from the first reservoir after a first threshold pressure is reached.
In some embodiments, the first plunger has a first concentration of the electrically conducting element and wherein the second plunger comprises a second concentration of the electrically conducting element.
In some embodiments, the first plunger has a first electrical impedance and the second plunger has a second electrical impedance.
In some embodiments, the first electrical impedance is indicative of a first drug and wherein the second electrical impedance is indicative of a second drug, the second drug different from the first drug.
Some embodiments pertain to an infusion set for delivering a single or multiple medicaments to a patient comprising a base set. In some embodiments, the base set comprises one or more of a first base unit having a first port and a first adhesive portion. In some embodiments, the first base unit comprises a first piercing element configured to deliver a first medicament to the patient. In some embodiments, the first adhesive portion is configured to adhere the first base unit to the patient.
In some embodiments, the infusion set comprises a second base unit having a second port. In some embodiments, the second base unit comprises a second adhesive portion configured to adhere the second base unit to the patient.
In some embodiments, the infusion set comprises a connector set. In some embodiments, the connector set comprises a first connector configured to reversibly couple to the first base unit via the first port and to provide a first fluid path from a first medicament infusion to the first port of the first base. In some embodiments, the connector set comprises a second connector configured to reversibly couple to the second base unit.
In some embodiments, the first base unit comprises a first guide member that prevents engagement of the second connector to the first base unit In some embodiments, the second base unit comprises a second guide member that prevents engagement of the first connector to the second base unit. In some embodiments, the first base unit and the second base unit are able to move independently with respect to each other and are configured to fit contours of the patient's body during movements made by the patient.
Various embodiments are depicted in the accompanying drawings for illustrative purposes, and should in no way be interpreted as limiting the scope of the embodiments. Any features, structures, components, materials, and/or steps of any of the embodiments can be combined or replaced with any features, structures, components, materials, and/or steps of any other of the embodiments to form additional embodiments, which are part of this disclosure.
Some embodiments described herein pertain to infusion systems, medicament loading systems, and methods for introducing or infusing medicaments and to provide proper channeling medicaments to patients.
A drawback of multi-medicament (e.g., pharmaceutical, hormone, etc.) and certain single medicament regimens is that the patient or physician may accidentally load, transfer, and/or administer the incorrect medicament. For instance, a user may mistakenly believe that he or she is providing one medicament when they are accidentally supplying a different one. The accidental administration of the incorrect medicament to the patient can have serious and potentially fatal consequences. For example, standard-of-care insulin therapies for regulating blood glucose in diabetic patients may involve subcutaneous infusion of insulin via an insulin pump. If the amount of dosed insulin is excessive, it can lead to hypoglycemia or a situation of impending hypoglycemia. To combat and/or reverse such adverse situations, individuals typically consume additional carbohydrates (e.g. sweet juice or glucose tablets). In some situations, individuals can alternatively and/or additionally administer a so-called “rescue dose” of a counter-regulatory agent, such as glucagon. A counter-regulatory agent combats the effect of the excess medicinal dose (e.g., excess insulin) alleviating or substantially preventing adverse effects related to the excess dose. Glucagon can be reconstituted into solution from an emergency kit and manually administered intramuscularly. If a patient is given additional insulin instead of a rescue dose of glucagon, the results could be catastrophic, potentially leading to death. Similarly, during a diabetic episode, if a patient requires insulin but is given glucagon instead accidentally, that administration could exacerbate the episode and could lead to devastating effects and potentially death.
As illustrated above, the proper channeling in medicament dosing is critical where one medicament is used to achieve one effect while the other is used to achieve a different and/or the opposite effect (e.g., in the case of insulin and glucagon). In a multi-medicament automated system, if the medicaments are accidentally loaded in the incorrect reservoirs or incorrect chambers of a pump, the automated system could deliver an ineffective (and potentially harmful) medicament to the patient. This phenomenon of incorrect medicament administration in automated systems is called cross-channeling. Cross-channeling is dangerous because the wrong medicament could have the opposite of the intended effect or a side effect that is unanticipated. This improper channeling could not only fail to alleviate the patient's condition, but could make the patient's condition worse, or cause a new problem-state for the patient. For instance, this improper channeling could cause a negative feedback loop, wherein the control system attempts to adjust the patient's disease state in one direction, but the delivery of the incorrect medicament exacerbates or causes no effect on the disease state. Sensing this, the control system can trigger further doses of the wrong medicament in an attempt to control the patient's condition, while actually causing the patient's condition to further deteriorate (or causing overdosing of the incorrect medicament).
While diabetic drugs are used as an example above and elsewhere herein, improper channeling can have deleterious effects in many multi-medicament regimens (e.g., in drugs that regulate pancreatic enzymes, etc.) because a medicament is not administered to the patient at the necessary time or an incorrect medicament is administered at a dangerous level. Thus, the embodiments and considerations provided herein can be applied to any drug individually and/or any drug combination. Additionally, while cross-channeling can refer to systems where two medicaments are inserted into the incorrect chambers of a distribution system, the term cross-channeling as used herein can also refer to systems were more than two medicaments are used and/or where a single medicament is used (for example, when a single medicament is improperly placed in a distribution system).
Described herein are infusion systems for multiple medicaments (or single medicaments) and various connectors, tubes, and cartridges that ensure, help ensure, and/or substantially aid in providing proper channeling of each medicament to the patient. While certain embodiments, of infusion systems and components are described below to illustrate various examples that may be employed to achieve one or more desired improvements, these examples are only illustrative and not intended in any way to restrict the general inventions presented and the various aspects and features of these inventions. The phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. No features, structure, or step disclosed herein is essential or indispensable.
Certain embodiments of the infusion systems and components described herein are configured to minimize, lessen, and/or otherwise help avoid the occurrence of cross-channeling of medicaments. In other words, where multiple medicaments are supplied by the infusion systems disclosed herein, the features and/or components described herein are configured to prevent, minimize the occurrence of, or otherwise inhibit the opportunity for a user to inadvertently place a medicament in the incorrect reservoirs. In some embodiments, one or more benefits of the infusion systems and components disclosed herein can be realized when a single medicament is used in the system. Additionally, the strategies described herein are also applicable to systems with single medicaments. In other words, in some embodiments, as noted elsewhere herein, reference to systems that prevent “cross-channeling” also can include systems employing a single medicament. In some embodiments, for example, the infusion systems disclosed herein provide a single medicament infusion system that, using the strategies and/or design features disclosed herein, ensure that only that single, appropriate medicament can be used and that inappropriate and/or incorrect medicaments cannot be used. Thus, in some embodiments, the systems disclosed herein that avoid cross-channeling are intended to include single medicament systems that ensure proper placement (and/or channeling) of single medicaments.
Some embodiments described herein pertain to an infusion system for dosing multiple medicaments (or a single medicament) without cross-channeling. In some embodiments, cross-channeling is avoided by providing design features and/or mating connectors or adapters on certain components of the infusion system. For instance, in some embodiments, the infusion system comprises an infusion pump with one, two, or more infusion chambers (or pump chambers), drive shafts. In some embodiments, the system further comprises cartridges filled with different medicaments, and connectors and tubing that connect to the cartridge to the infusion pump in such a way as to prevent mischanneling or cross-channeling of medicaments. In certain variants, each type of cartridge for each type of medicament has one or more unique differentiating features (either as an integral part of the cartridge or as a component attached or affixed to the cartridge), for example geometric or shape-based features, that allow for unique coupling with a type of connector that itself has unique differentiating features that engage corresponding features in the pump housing and allow for insertion of the proper cartridge into the proper infusion chamber, drive shaft, or pump chamber within the infusion pump.
In certain variants, the system comprises an infusion set. In some embodiments, the infusion set comprises a base with a housing having one or more implements (e.g., delivery members, needles, etc.) that allow delivery medicaments to the patient from the system. In some variants, the housing is connected to a distribution set comprising one or more distribution connectors that are configured to receive a medicament from one or more medicament reservoirs (e.g., via a conduit etc.). In some embodiments of the system, one or more fluid conduits provide fluidic communication between the reservoirs and a distribution connector set. In various implementations, the connector set comprises one or more cartridge connectors that couple the fluid conduits to the medicament reservoirs. In some variants of the system, the reservoirs (or reservoir) are located in (and/or can be placed in) a pumping device configured to distribute the medicament from the reservoirs (or reservoir) to the conduit, thereby supplying the system with medicaments. In some embodiments, the fluid conduits provide separate pathways that terminate at designated delivery members (e.g., needles, cannulas, etc.) within the base, thereby enabling independent delivery (e.g., subcutaneous or otherwise) of medicaments separately.
In some embodiments, unique mating connectors and design elements ensure that each portion of the system can only be connected within the system in a unique way or configuration, thus preventing the cross-channeling. In certain embodiments, the design features give rise to the following advantages: (1) the infusion system allows the user to easily connect and disconnect the channels independently from both medicament sources as well as from the infusion ports or sites; (2) the infusion system mitigates the possibility of mischanneling by accidentally connecting the wrong tubing to the wrong medicament source or infusion site (e.g., by having a connector that is disposed between one tube and one pump reservoir of one medicament system differ from the connector of the other tube and reservoir); and (3) the infusion system allows for a single or multistep insertion of the dual-cannula infusion site or port. In some embodiments, the components described herein (connectors, bases, ports, channels, etc.) can further comprise visual or brail call-outs in addition to or instead of various paired physical features disclosed herein. For instance, in some implementations, the components can comprise call-outs with wording indicating a proper medicament. In some variants, different colors (red, blue, yellow, green, orange, violet, etc.) or lengths (or other variables) to provide visual feedback regarding appropriate medicaments for appropriate components.
In some embodiments, as stated above, the infusion system can be used to provide separate fluid pathways for a variety of medicaments (e.g., drugs, hormones, proteins, pharmaceuticals, biologics, etc.) dissolved in a variety of liquid carriers (and/or liquid drugs). In certain embodiments, different liquid vehicles may be preferred based on the solubility, stability, or sensitivity of the medicament in a particular carrier. In some embodiments, aqueous solutions (buffers, etc.) are used as a delivery vehicle for the medicament. In certain variations, solvents such as DMSO are used to dissolve medicaments. In some embodiments, solvent/aqueous mixtures are used.
Some embodiments disclosed herein pertain to an infusion system for preventing mischanneling of medicaments and/or inadvertent administration of a medicament. In some embodiments, the infusion system can be used for multiple medicaments or a single medicament. In some embodiments, the infusion system comprises various needle sites, connectors, tubes, and/or cartridges. In some embodiments, the infusion system and/or components thereof ensure proper channeling of each medicament to the patient. In some embodiments, the infusion system comprises an infusion pump. In some embodiments, the infusion pump comprises one, two, or more pump chambers. In some embodiments, the infusion pump is configured to be used with pump cartridges. In some embodiments, the cartridges can be filled at the point of care with different medicaments (or may be pre-filled with different medicaments, for example, at a pharmaceutical company). In some embodiments, different connectors and/or tubing can connect the cartridges to the infusion pump in such a way as to prevent mischanneling and/or cross-channeling of medicaments. In some embodiments, each type of cartridge for each type of medicament has unique differentiating sizes, shapes, and/or geometrical features (either as an integral part of the cartridge or as a component attached or affixed to the cartridge) that allow for unique coupling with a type of connector. In some embodiments, each connector itself has unique differentiating features that engage corresponding features in the pump housing. In some embodiments, each connector only allows for insertion of the proper cartridge into the proper pump chamber within the infusion pump.
In some embodiments, the medicament infusion system comprises an inlet system. In some embodiments, the inlet system comprises a connector set. In some embodiments, the connector set is configured (e.g., has pairing features) that prevent mischanneling of medicaments.
In some embodiments, these unique differentiating guiding elements 2018, 2118 (e.g., tabs, features, or protrusions) mate uniquely with corresponding guiding element apertures 681, 682 (e.g., cavities, grooves, keyways, or slots) in the pump housing 680 of a pump 651 (as shown in
In some embodiments, as shown in
In some variants, where multiple relief slits are present, the relief slits can be spaced unevenly about the collar so that some projections are closer and some are farther. In some embodiments, adjacent relief slits are separated by values independently selected from greater than or equal to: about 180°, about 160°, about 140°, about 120°, about 100°, about 90°, about 80°, about 70°, about 60°, about 50°, about 40°, about 30°, about 20°, about 10°, values between the aforementioned values or otherwise. In some embodiments, this inlet connector spacer allows the inlet connector to be compressed as it inserts into a pump housing or expanded as it is slid over a collar/reservoir assembly. This can allow snap tight fitting into a pump housing or with a collar/reservoir assembly that comprises mated features. For instance, in some embodiments, once inserted all the way into the housing, the inlet connector spacers can re-expand, allowing the geometric features of the inlet connector to interact with mated apertures or features of the pump housing. This feature, among others described herein, can allow the reservoir to be held in an appropriate position, with little movement and/or substantially without movement, within the pump housing. In some embodiments, the relief slits allow the inlet connector to be pressed over the head (or crown) of the cartridge. In some embodiments, a locking mechanism snaps the inlet connector in place as it engages with the underside of the head (or crown) of the cartridge.
In some embodiments, the needle connector has any number of unique differentiating tabs, features, protrusions, and/or combinations thereof, as in
In some embodiments, as shown in
In some embodiments, an inlet connector, such as the ones shown in
In some embodiments, as shown in
In some embodiments, an elastomeric plunger 550 creates a sterile barrier and fluid seal on the other end of the cartridge 530. In some embodiments, the elastomeric plunger 550 has a receptacle 552′ that captures (e.g., through threading, friction, etc.) an insert 560 (e.g., a magnetic insert). In some embodiments, as shown, the insert 560 (e.g., the ferrous insert) is threaded to correspond and engage paired threads on the plunger 550. In some embodiments, the insert 560 could be used with a coupled piston (e.g., magnetically coupled) to prevent accidental medicament delivery caused by inadvertent separation of the piston from the elastomeric plunger 550. In some embodiments, this insert which can comprise a magnetic material (e.g., a ferrous material and/or metal shavings, metal beads, metal powder, etc.) can facilitate magnetic coupling between a magnet at the end of the drive nut in a pump chamber and the elastomeric plunger such that it would prevent inadvertent departure or lift-off of the elastomeric plunger from the drive nut as in the case of unintentional medicament delivery caused by gravitationally induced changes in hydrostatic pressure between the patient and the infusion system, or any other changes in hydrostatic pressure that might arise between the patient and the infusion system. In some embodiments, the ferrous insert could be connected to the elastomeric plunger by means of a snug-fit or snap-fit. In some embodiments, the ferrous material comprises and/or is iron in the form of shavings, bead, powder, etc.
In some embodiments, the inlet connector 2010 (i.e., needle connector) by virtue of its relief slits 2136 can expand around the head 532 (or crown) of the cartridge fitted with the crimp seal 536 allowing its capture-and-locking features/projection mate 2066 to snap into place by engaging the underside of the aluminum crimp seal 536 and simultaneously interlocking and securely fastening the inlet connector 2010 with the aluminum crimp seal 536. The cartridge and needle connector sub-assembly can be inserted into a pump housing and the threaded coaxial cap 2030 which is free to slide along the tubing 301, shown in
As discussed above,
In some embodiments, the fully assembled cartridge, needle connector, and tubing system (comprising a straight, beveled, hollow, stainless steel needle, a cartridge fastened to the needle connector with a capture-and-locking feature, tubing, and a threaded coaxial cap), inserts into a pump chamber of a pump housing that contains corresponding cavities, grooves, keyways, or slots to match the unique differentiating tabs, features, or protrusions on the needle connector (as shown in
In some embodiments, the reservoirs can comprise a sticker, engraving, or label that comprises a readable code (e.g., a quick response code, matrix barcode, sku, barcode, image, other computer readable code, etc.). In some embodiments, the pump 651 comprises a reader (e.g., an optical reader, scanner, etc., not shown) that reads the readable code when the reservoir is inserted into a pump chamber (e.g., a pump receptacle 660, 670). In some embodiments, where the code is recognized as being incorrect for a particular chamber or setting of the pump, the pump does not activate or stops operation (e.g., if the wrong code is present). In other embodiments, where the code is recognized as being incorrect for the current pump parameters (e.g., or amount of infusion per unit time, etc.), the pump is configured to automatically reconfigure to change the pump parameters to accommodate the actual medicament (e.g., cartridge) that is inserted. In some embodiments, the pump provides an indication (e.g., audible, visual, haptic, vibrational, etc.) that alerts the user that the incorrect medicament is inserted. In some embodiments, the user is then prompted to and/or is able to select a new setting for the pump to accommodate the new medicament (e.g., from a drop-down display on an LCD screen of the pump, etc.). In some embodiments, software and/or a computer application activates adjust the pump parameters to accommodate the medicament that has been inserted. For illustration, in some embodiments, where the pump is configured to inject U100 insulin, but reads that U200 cartridge is inserted, the pump can change the delivery parameters to accommodate proper delivery of the U200 insulin from its reservoir. As another illustration, in some embodiments, where the pump is configured to inject a rapid-acting insulin, but reads that ultrarapid-acting insulin cartridge is inserted, the pump can change the delivery parameters to accommodate proper delivery of the ultrarapid-acting insulin from its reservoir.
In some embodiments involving two medicaments, the cartridge (e.g., cartridge A) containing one medicament (e.g., medicament A) has larger internal and external diameters than the corresponding diameters of the other cartridge (e.g., cartridge B) containing the other medicament (e.g., medicament B) (as shown in
In some embodiments involving two medicaments, the needle connector intended for cartridge B contains a skirt feature 2320 (as shown in
In some embodiments involving two medicaments, the diameter of the aluminum crimp seal around the crown of one cartridge is identical to that of the other cartridge, but the height of the aluminum crimp seal around the crown of cartridge B is greater than that of cartridge A, such that the capture-and-locking feature 2366 within the needle connector 2310 intended for cartridge A will not be engaged if the needle connector intended for cartridge A is accidentally placed on cartridge B (not shown).
In some embodiments, as shown in
Throughout this disclosure, similar features for separate embodiments of a device component (e.g., inlet connectors, inlet connector covers, etc.) can comprise one or more coinciding features offset numerically by a factors of 100 but having the same tens numerical value. For example, features of inlet connector 2030 that coincide to similar features of another connector 2130 will be offset by a 100, respectively (e.g., feature 2012 corresponds to 2112, etc.).
In some embodiments (as shown in
In some embodiments, the tubing 301 passes through a threaded coaxial cap 2030, 2130, 2230, 2330, which is free to slide up and down the threaded coaxial cap and thread into a pump housing.
In some embodiments, the fully assembled cartridge assembly, comprising a cartridge, needle connector, and tubing system (consisting of a straight, beveled, hollow, stainless steel needle, a cartridge fastened to the needle connector with a capture-and-locking feature, tubing, and a threaded coaxial cap, as shown in
In some embodiments, a medicament reservoir filling system and method of using the same is provided, as shown in
In some embodiments that utilize a needle transfer hub to transfer medicament from a vial to the cartridge, as in
In some embodiments that utilize a needle transfer hub to transfer medicament from a vial to the cartridge, two separate, straight, beveled, hollow, stainless steel needles are overmolded, bonded, press-fitted, glued, solvent bonded, insert molded, or otherwise attached to the needle transfer hub in such a way as to allow a closed, independent, patent, and continuous fluid path through the straight, beveled, hollow, stainless steel needles. In some embodiments, each straight, beveled, hollow, stainless steel needle would be beveled only on one tip, where the beveled tip of one needle would be designed to pierce the septum of the cartridge and the beveled tip of the other needle would be designed to pierce the septum of the vial. In some embodiments, the tip that is designed to pierce the septum of the cartridge is recessed within the needle transfer hub so as to be touch-proof and the tip that is designed to pierce the septum of the vial can be concealed and protected by a needle guard which is to be removed at the point of care before piercing the septum of the vial. Alternatively, in some embodiments, the tip that is designed to pierce the septum of the vial can also be recessed so as to be touch-proof and a needle guard may not be supplied.
In some embodiments, involving two medicaments, mischanneling of medicaments can still be avoided if cartridge B is pre-filled with one medicament and cartridge A is filled at the point of care with a different medicament (using the embodiment described in
In some embodiments, the same dual-medicament infusion system could use identical needle sites, connectors, tubes, and cartridges in the configuration where both cartridge A is pre-filled with medicament A and cartridge B is pre-filled with medicament B, as in the configuration where cartridge A is filled at the point of care with medicament A and cartridge B is pre-filled with medicament B (or vice versa).
In some embodiments (as in
In some embodiments (as in
In some embodiments, as shown in
In some embodiments, as discussed elsewhere herein, a magnetic coupling between a magnet (or magnetic portion) at the end of the drive nut 2700 (located in a pump chamber of a pump) and the elastomeric plunger 550 occur to prevent inadvertent departure (or lift-off) of the elastomeric plunger 550 from the drive nut 2700. This coupling advantageously prevents the plunger from moving and distributing medicament in an uncontrolled and/or undesired way. For instance, medicament vials having plungers are typically designed to have little or no resistance and/or friction between the plunger and the wall of the reservoir. Thus, the plunger can move and distribute medicament with very little force applied to the plunger (e.g., even by moving the cartridge). In some embodiments, configurations described herein avoid issues with low friction plungers by coupling (e.g., magnetically) the plunger to the drive nut. In some embodiments, as discussed elsewhere herein, a ferrous insert 565 can be screwed into the plunger 565 of the cartridge 530. In some embodiments, a perceivable click (by touch, sound, etc., or other indication as described elsewhere herein) occurs when the magnetic tip of the drive nut and the magnetic insert come into contact. This click and/or mating can indicate to a user that the vial is properly placed in the pump.
In some embodiments, the magnetic insert 565 (e.g., ferrous insert) can be injection-molded and/or can comprise, in part, a curable material that is cured during fabrication. In some embodiments, during fabrication of the magnetic insert 565, a curable material (e.g. uncured plastic, rubber, elastomer, polymer, epoxy, composite, etc.) is mixed with a magnetic material (e.g., a ferrous material, metal shavings, metal beads, metal powder, etc.). During mixing, the magnetic material can be distributed homogeneously and/or as a gradient throughout the curable material. In some embodiments, the curable material can then be cured to provide a magnetic insert 565 with magnetic material distributed within the cured material.
In some embodiments, by using a polymeric insert (e.g., plastic, rubber, elastomer, composite, etc.) that is loaded with magnetic material (e.g., a ferrous material, metal shavings, metal beads, metal powder, etc.), a desired strength of association between the magnetic tip 2702 and the magnetic insert 565 can be achieved. In some embodiments, a tailored magnetic coupling between the insert 565 and the magnet 2703 at the magnetic tip 2702 of the drive nut 2700 (as shown in
In some embodiments, the magnetic material can be directly dispersed within the plunger 550 during fabrication of the plunger. For example, during fabrication of the plunger, magnetic properties can be added to the plunger material prior to and/or during molding. In some embodiments, this obviates the need for insert 565 having magnetic properties. In some embodiments, this advantageously simplifies the system and avoids additional steps needed for coupling an insert to a plunger.
In some embodiments, using an insert with magnetic properties that is placed within plunger advantageously prevents contact between the medicament in the reservoir and the magnetic material. In some embodiments, using an insert 565 with magnetic properties in the plunger 550 (instead of a magnetic material distributed in the plunger) advantageously prevents leaching of the magnetic material into the medicament by preventing contact between the magnetic material and the medicament. In some embodiments, using an insert configuration also improves the integrity of the reservoir. In some embodiments, for example, when the reservoir is filled by a patient or at the point of care, the plunger is depressed and retracted multiple times. In some embodiments, when distributed directly in the plunger, the magnetic material abrades the inner chamber of the vial after multiple uses. This abrasion can lead to premature failure of the vial and/or leaking of the reservoir assembly. In some embodiments, using the insert with magnetic properties in the plunger avoids this abrasion. In some embodiments, an insert having magnetic properties can be an integral, but separate, component embedded within the elastomer plunger such that there would be no need to manually insert it into the plunger at the point of care (i.e. the plunger would come with the insert already installed by the manufacturer during the fabrication of the plunger/insert assembly).
In some embodiments, a method of detecting and continuously monitoring contact between the elastomeric plunger or insert 565 and the drive nut 2700 in each pump chamber is provided. In some embodiments, for instance, the insert 565 (or plunger) is made of electrically conductive plastic (e.g., a plastic containing carbon fibers, metal strands, shavings, copper filings, etc.) and it serves as a conducting element that can complete a passive electrical circuit. In some embodiments, mating components of the passive circuit could be installed on the tip 2702 of the drive nut 2700 in each pump chamber. In some embodiments, the passive electrical circuit on the tip 2702 of the drive nut 2700 could be powered remotely by an active circuit installed somewhere within the pump housing (e.g. using some form of radiofrequency identification or “RFID” such as a near-field communication protocol). In some embodiments, in the absence of the electrically conductive insert 565 (or plunger), current would not flow through the passive electrical circuit on the tip 2702 of the drive nut 2700. In some embodiments, contact between the electrically conductive insert 565 (or plunger) and the passive electrical circuit on the tip 2702 of the drive nut 2700 would close the passive circuit and allow current to flow through the passive circuit and through the electrically conductive insert 565 (or plunger).
In some embodiments, the change in status from a no-current-flow state to a current-flow state would correspond to a change in status from a no-contact to a contact configuration between the electrically conductive insert 565 (or plunger) and the tip 2702 of the drive nut 2700. In some embodiments, if a drug cartridge is placed into the pump chamber and the insert 565 is not present, this detection mechanism could place the pump into a fault state. In some embodiments, the fault state could prevent the pump from operating (preventing medicament flow). In some embodiments, the fault state triggers an alarm feature that could alert the user of the error (e.g., a vibration, audible alarm, visual alarm, etc.). In some embodiments, if the elastomeric plunger 565 lifts off of the drive nut 2700 during operation, this detection mechanism could also place the pump into a fault state, and an alarm could alert the user of the error.
In some configurations, the elastomeric plunger insert 550 (shown in
In some embodiments, as an alternative configuration and as shown in
Additionally, the electric circuit configuration can allow users to avoid inserting incorrect cartridges (e.g., medicament vials) into the pump and using them with the infusion system. For example, if a user attempts to insert a vial having medicament reservoir with the incorrect plunger into the pump (e.g., a reservoir lacking a magnetic and/or conductive insert), the pump remains in the no-contact mode and does not distribute the medicament. In some embodiments, this feature can also act as a safe guard to ensure that only proper vials are used in appropriate ports of the pump (avoiding mischanneling, etc.). This feature can help avoid distribution of the incorrect medicament to a patient.
In some embodiments, an alternative and/or additional method for detecting the presence of the plunger of a cartridge (and/or the presence of a cartridge itself), is to initiate a detection sequence before attempting to administer a dose. For example, in some embodiments, the detection sequence can involve applying a limited driving electrical current. In some embodiments, the limited driving electrical current could be one that is just sufficient to advance the drive nut when not in contact with a cartridge plunger. In other words, the limited driving electrical current could be one that is insufficient to advance the drive nut when in contact with the cartridge plunger. In some embodiments, for example, where the plunger is present, it has sufficient static friction and/or flow resistance downstream (whether due to friction within the cartridge body, neck, connector, or connected tubing, and/or from added features within these components, such as a check valve, etc.) and resists and/or substantially prevents the advancement of the drive nut. In some embodiments, once the plunger is detected, the electrical current can detectably ramp up and/or enter a delivery mode (where the pump is configured to distribute medicament into the patient). In some embodiments, this detection process could be repeated just in advance of each medicament dosing attempt to ascertain whether or not the plunger (and/or an appropriate plunger) and/or insert is present and/or in contact with the drive nut. Then, depending on whether the plunger and/or insert is detected or not, the pump could respond accordingly (e.g. by dosing if plunger is detected, or by aborting the dose and/or annunciating an alarm if plunger is not detected to be present). In some embodiments, the detection sequence and the control of the electrical current described above can be implemented using a controller. The controller is described more in detail elsewhere herein.
In some embodiments, the detection sequence involves a probing sequence. In some embodiments, the probing sequence involves the advancement of the drive nut, as described elsewhere herein, to first detect the plunger. In some embodiments, once the plunger is detected, the type of plunger can be determined by retracting and advancing the drive nut incrementally until a force and/or current sufficient to just move the plunger is reached. For example, in some embodiments, plungers for varying reservoirs for different medicaments can have different resistance (e.g. frictional and/or due to resistance offered by other reservoir and/or connector components that correspond to that specific reservoir and medicament) to movement by the drive nut. Based on the level of resistance, through the amount of electrical current required to advance the plunger, the type of medicament can be detected. For illustration, in some embodiments, the drive nut is advanced until it detects the plunger. Once the plunger is detected, the drive nut can either be retracted and/or advanced short distances (e.g., tapping of the plunger) until a sufficient force and/or current is generated and/or applied to move the plunger or its pushing against the plunger can be gradually increased (i.e. driving current escalated, without first retracting the plunger) until a sufficient force and/or current is generated and/or applied to move the plunger. Based on the force (in turn the corresponding required electrical current draw) required to move the plunger, the type of medicament in the pump receptacle can be detected. As an exemplary demonstration, four different medicaments can be provided in four different reservoirs with plungers that move in response to four different levels of force applied to the plungers (and/or current applied to the drive nut). The first medicament reservoir plunger can move in response to a lowest applied force and/or current, the second medicament reservoir plunger can move in response to a second slightly higher applied force and/or current, the third medicament reservoir plunger can move in response to a third slightly higher applied force and/or current, and the fourth medicament reservoir plunger can move in response to a fourth and highest applied force and/or current. If the third medicament reservoir is placed in the pump, the drive nut can probe the amount of force and/or current required to move the plunger with tapping (e.g., successive advancement and retraction of the drive nut) or by gradual escalation of the force and/or current as the drive nut remains in contact with the plunger (without retraction). The first, second, and fourth medicaments can be eliminated as potential medicaments in the pump by virtue of the plunger moving in response to a force/current corresponding to that required to move the plunger of the third medicament reservoir. In other words, the controller and drive nut can be configured to tap/push with the lowest force, escalate to a different force/current, and move to the next force/current until the proper amount of applied force/current is determined.
In other embodiments, one or more of the medicament reservoir detection methods described elsewhere herein can be used in combination with the detection sequences and/or probing sequences described here to determine the type of medicament in the reservoir receptacle of the pump (e.g., an optical code reader, RFID, etc.). In other embodiments, one or more of the medicament reservoir differentiation methods described elsewhere herein (e.g., an optical code reader, RFID, etc.) can be used in combination with the detection method described here to determine the type of medicament in the reservoir receptacle of the pump.
In some embodiments, in addition to or instead of one or more features of the plunger inserts described elsewhere herein, a plunger insert may also include features that give them identifiable electrical impedances (or electronic properties). In some embodiments, an insert's electrical impedance (controlled by the amount of conducting material placed into the insert, for example, during the manufacturing process) can be set and used as a unique identifier of the specific drug and/or of a specific drug property of a specific drug contained in a cartridge that includes that plunger insert. For example, in some embodiments, a variety of plunger inserts could be fabricated with different impedance levels and each impedance level could be matched with a different drug or drug property (or set of properties) of the same drug (e.g. at a different concentration, pH, excipient content, or other properties, etc.). To illustrate, a first drug could be provided in a first cartridge having a plunger with a first electrical impedance. A second drug, alternatively could be provided in a second cartridge having a second plunger with a second electrical impedance (the second electrical impedance being different from the first). Additionally, a third medicament cartridge could be provided containing the second drug at a different concentration than in the second cartridge. The third cartridge would have a third electrical impedance that is different from the first and second impedances, making each cartridge distinguishable from the next. In some embodiments, for a given voltage applied to the insert, a unique electrical current would arise for a particular plunger insert's impedance. A particular electrical current can then be linked to a specific drug and/or specific drug property (or set of properties) contained in the cartridge. These particular impedances could be mixed and matched with other features disclosed herein to give various different receptacles that avoid cross-channeling.
In some embodiments, where electrical impedance is used as an identifier for a particular drug or drug property, the matching keyset that associates each plunger insert's resultant electrical current with its corresponding drug could then be loaded into the infusion pump's software, such that the infusion pump is able to automatically identify the specific drug that is resident in the cartridge once it is loaded into the infusion pump. In some embodiments, with this method, the pump can autonomously distinguish among the drugs and/or their properties and/or could self-initialize its dosing settings accordingly, without requiring or being vulnerable to user input. Independently from this electrical impedance feature, the various plunger inserts could additionally or alternatively have different distinguishing features (as described elsewhere herein) so that each uniquely mates with matching features in the cavity of its corresponding plunger, so as to match different inserts that have different impedance levels with different plungers.
In some embodiments, a magnetic insert can be installed in the plunger. In some embodiments, the polarities of the magnetic insert and the magnet in the drive nut can be oriented to attract one another (e.g., north and south) or to repel one another (e.g., so their polarities are repulsive; e.g., south/south or north/north). In some embodiments, the magnetic insert of a medicament vial is oriented to only attract and couple to the magnet of a drive nut in the correct medicament pump aperture. Alternatively, when inserted into the incorrect medicament pump chamber, the magnetic insert repels the magnet of the drive nut. Thus, the incorrect medicament vial cannot be placed in the wrong chamber. Additionally, the electric circuit (where present) cannot be completed, thereby preventing infusion of the medicament. In some embodiments, these configurations prevent medicament misplacement and prevent infusion of the incorrect medicament.
In some embodiments, where two medicaments are to be provided using the infusion system, mischanneling can be avoided by orienting the magnetic inserts to repel incorrect medicament reservoirs and to attract only the correct medicament reservoirs. For example, a magnetic insert of the first medicament reservoir can be oriented such that it repels a magnetic tip of the drive nut in the second medicament pump cartridge aperture (e.g., chamber). Additionally, in some embodiments, a magnetic insert of the second medicament reservoir can be oriented such that it repels a magnetic tip of the drive nut in the first medicament pump cartridge aperture (e.g., chamber). In some embodiments, by avoiding insertion into the wrong chamber of the pump, the patient reduces the risk of infusing the incorrect medicament
In some embodiments, as described elsewhere herein, during fabrication of a magnetic insert 565, a curable material (e.g. uncured plastic, rubber, elastomer, polymer, epoxy, composite, etc.) is mixed with magnetic filings. During mixing, the magnetic filings can be magnetically aligned using an external magnetic dipole so that a magnetic pole is formed in the curable material. In some embodiments, the curable material can then be cured to provide a magnetic insert 565 having a magnetic north and a south pole distributed within the cured material. In some embodiments, this cured insert repels the magnetic drive nut in the incorrect pump chamber and attracts the drive nut in the correct pump chamber.
In some embodiments, the magnetic insert can be configured (e.g., shaped, etc.) to only interact with an appropriate, pre-selected cartridge plunger (e.g., having coinciding, pairing features). For example, when two cartridges (A and B) are both filled at a point of care, the magnets of the magnetic insert for A and the magnetic insert for B can be configured to only insert into a plunger cartridge for medicament A and a plunger cartridge for medicament B, respectively. In some embodiments, the plunger of cartridge A and the plunger of cartridge B can have one or more differentiating features that prevent engaging the incorrect magnet insert. For illustration, magnetic insert A can have features (e.g., threads, clips, clamps, etc.) that coincide to mating features on plunger A and not plunger B. Magnetic insert B can have features (e.g., threads, clips, clamps, etc.) that coincide to mating features on plunger B and not plunger A. In some embodiments, one pair (the plunger and insert) can be threaded in the forward direction and the other pair in the reverse direction. In some embodiments, these differentiated magnetic inserts ensure that magnets are inserted correctly to attract a correct magnetic tip of a drive nut (in a correct pump chamber) and to repel an incorrect magnetic tip of a drive nut (in an incorrect pump chamber).
In some embodiments, as another measure to prevent inadvertent separation or lift-off of the elastomeric plunger 550 from the drive nut 2700 (as an additional or alternative measure), a check valve 2800 can be added to the fluid path within the cartridge or downstream of the cartridge. In some embodiments, the check valve 2800 allows fluid flow passed the check valve 2800 only if a sufficiently high pressure gradient were to exist (e.g., pressure supplied by the pump turning the lead screw and urging the plunger forward). In some embodiments, as shown in
In some embodiments, the membrane 2801 is flexible. In some embodiments, the membrane 2801 is also resilient. In some embodiments, the membrane 2801 is rubber, plastic, polymeric, elastomeric, combinations thereof, or the like. In some embodiments, when the plunger is not urged forward, the membrane 2801 rebounds to its original shape and prevents fluid from traveling through the needle 316 and into the tubing 301.
In some embodiments, the check valve comprises an opener feature 2802 against which the diaphragm 2801 presses when pressure mounts on the diaphragm 2801 from fluid being urged from the reservoir 530. In some embodiments, when the pressure is sufficient, the diaphragm 2801 deforms against the opener feature 2802 (e.g., a peg, spike, conical member, triangular member, etc.) to allow fluid (e.g., a medicament) to pass the diaphragm and escape via the tubing 301. In some embodiments, as shown in
In some embodiments, the check valve allows fluid to pass only after reaching a threshold pressure (e.g., a crack pressure). In some embodiments, the threshold pressure needed to allow fluid flow passed the check valve is greater than any gravitationally induced hydrostatic pressure differential that might develop between the patient and the infusion system. For instance, hydrostatic pressure can develop when the infusion system is connected to a patient via the infusion base and the patient (or user) lifts the loaded pump (containing one or more medicament vial(s)) to an elevation over the infusion base. By force of gravity, the elevation of the vial pushes fluid from the vial through the conduit and into the patient via the infusion base set. The amount of hydrostatic force applied is determined by the elevation of the medicament vial over the infusion set. The amount of hydrostatic force, therefore, is usually limited by the length of the fluid conduit (which ultimately connects the medicament vial to the infusion set). In some embodiments, a standard length of the fluid conduit is about 110 cm or about 60 cm. In some embodiments, the check valve is sufficiently resilient to remain closed when a vial of medicament in the infusion system is elevated over the infusion set by a distance of at least: about 220 cm, about 110 cm, about 60 cm, values between the aforementioned values, or ranges spanning those values. In some embodiments, the check valve is designed such that the threshold pressure gradient needed to allow fluid flow passed the check valve is greater than any hydrostatic pressure differential that might arise due to any other changes in the hydrostatic pressure between the patient and the infusion system (e.g., force caused by an airplane changing elevation, a carnival ride, bungee jumping, physical activity, etc.).
In some embodiments, as shown in
In some embodiments, a transient connection between the plunger and drive nut is provided. In some embodiments, the connection between the plunger and drive nut does not require and/or does not comprise a magnet and/or a ferrous insert. In some embodiments, the connection between the plunger and drive nut uses one or more features on the tip of the drive nut that connects to (e.g., couples with, fits inside, envelopes, engages, fixes to, etc.) the plunger and/or retains the plunger. In some embodiments, the connection between the plunger and drive nut is a physical connection (e.g, accomplished with threading, a snug-fit connection, a snap-fit connection, and/or a barbed connection) and is not magnetic.
In some embodiments, an optical sensor detects the presence of a medicament reservoir. In some embodiments, the optical sensor detects, for example, the proximity of the plunger to the drive nut. In some embodiments, the optical sensor detects a feature of the plunger (e.g., shape, color, etc. of the insert or plunger). In some embodiments, the optical sensor is in electronic communication with a software module that determines when/if there is contact with the plunger and/or that the correct plunger is being used (e.g., the correct plunger within the reservoir). In some embodiments, once receiving input from the optical sensor and determining if the proper reservoir is inserted, the pump activates (when the proper medicament is inserted) or deactivates (when the improper medicament is inserted). In some embodiments, as disclosed elsewhere herein, once an improper medicament is detected, the pump can automatically reconfigure to provide the correct dosing regimen of the inserted medication. In some embodiments, once an improper medicament is detected, the pump or a display on the pump can indicate to the user that the improper medicament has been placed in the pump. In some embodiments, the user can manually reconfigure the pump to provide the correct dosing regimen of the inserted medication.
In some embodiments, the drive nut comprises a mechanical switch (e.g., on the tip of the drive nut) that can be activated (e.g., depressed, displaced, moved, etc.) when it contacts a plunger. In some embodiments, the mechanical switch is configured to only be activated by appropriate medicament reservoirs (e.g., because incorrect reservoirs are not shaped appropriately to depress the switch). For example, in some embodiments, switch is located at the center of the drive nut and a non-matching (e.g., incorrect) medicament reservoir comprises a hood or sash that elevates the plunger of the medicament reservoir over the switch such that the switch is not depressed as the drive nut contacts the reservoir. In some embodiments, the switch can be located on the plunger and can be activated by the drive nut. In some embodiments, the pump (e.g., an optical sensor in the pump, receiver, etc.) is configured to detect when the switch of the plunger is actuated.
In some embodiments, the drive nut comprises a capacitive proximity sensor. In some embodiments, the capacitive proximity sensor is positioned on the tip of the drive nut. In some embodiments, the capacitive proximity sensor detects when the plunger is in proximity with and/or is contacted by the drive nut. In some embodiments, the capacitive proximity sensor indicates and/or detects when the drive nut and plunger are in close proximity and/or are substantially in contact with each other. In some embodiments, the capacitive proximity sensor detects when the plunger and the drive nut are separated by a distance of less than or equal to about: 2 mm, 1 mm, 0.5 mm, 0.1 mm, or ranges including and/or spanning the aforementioned values. In some embodiments, when a cartridge is inserted and the proximity sensor does not detect the plunger (e.g., because one or more features on the cartridge, the plunger, and/or drive nut prevent the proximity sensor from coming into close enough proximity to the plunger to detect it), an indication is provided to the user (e.g., an alarm that is audible, visual, haptic, vibrational, etc.). In some embodiments, when a cartridge is inserted and the proximity sensor does not detect the plunger (e.g., because one or more features on the cartridge, the plunger, and/or drive nut prevent the proximity sensor from coming into close enough proximity to the plunger to detect it), the pump automatically retracts the drive nut away from the cartridge. In some embodiments, once the drive nut is retracted, the pump will not allow the drive nut to traverse forward until a new cartridge is placed in the pump chamber. In some embodiments, when the proximity sensor detects the plunger, an indication is provided to the user (e.g., an alarm that is audible, visual, haptic, vibrational, etc.).
In some embodiments, the reservoir or connector set comprises a microfluidic valve, an electronically activated valve, a solenoid valve, a hydro-mechanical operated valve, and/or pneumatic valve. In some embodiments, the microfluidic valve (or other valve) is actuated by the pump and allows flow when the drive motor is active. In some embodiments, the microfluidic valve (or other valve) is closed when the drive motor is inactive. In some embodiments, the active closing and opening of the actuating valve prevents inadvertent dosing when the drive motor is not active.
In another embodiment, redundant mechanisms could be put in place to prevent inadvertent separation or lift-off of the elastomeric plunger from the drive nut. In such an embodiment, the elastomeric plunger insert could be made of an electrically conductive material having magnetic properties (such as an electrically conductive plastic loaded with ferrous material), and a check valve could be integrated into the needle connector. Coupled with a magnet located at the tip 2702 of the drive nut 2700 in each pump chamber, and a passive electrical circuit installed on top of that magnet, which would be powered remotely via RFID from an active circuit installed somewhere within the pump housing, these systems could simultaneously serve to prevent inadvertent separation or lift-off of the elastomeric plunger from the drive nut, to capture the elastomeric plunger by the drive nut, and to detect (and continuously monitor) that the elastomeric plunger has been captured by the drive nut.
In some embodiments that utilize a needle transfer hub to transfer medicament from a vial to the cartridge, the body of the needle transfer hub could be manufactured from the same mold as the needle connector, except without the capture-and-locking feature as the needle transfer hub would need to be removed from the cartridge upon completing the filling procedure, whereas the needle connector would permanently capture the cartridge and would be disposed of along with the cartridge once the cartridge was emptied of its deliverable contents.
In some embodiments involving a single medicament or multiple medicaments, the inlet end of each tubing is overmolded, bonded, press-fitted, glued, solvent bonded, insert molded, or otherwise attached to a needle connector (e.g., the inlet connector) and the outlet end of each tubing is overmolded, bonded, press-fitted, glued, solvent bonded, insert molded, or otherwise attached together with an infusion site and a cannula that delivers the medicament or medicaments to the delivery area (e.g., delivery transdermally, intradermally, subcutaneously, intramuscularly, intravenously, etc.).
In some embodiments involving a single medicament or multiple medicaments, the inlet end of each tubing is overmolded, bonded, press-fitted, glued, solvent bonded, insert molded, or otherwise attached to a needle connector (as in
In some embodiments, the infusion set includes a connector cover 2434.
In some embodiments (as shown in
In some embodiments, a single-medicament implementation of the infusion system that infuses only medicament A can use one of the two single-medicament infusion site connectors of the dual-medicament infusion site connectors. Similarly, the other single-medicament infusion site connector, which is distinct from the single-medicament infusion site connector for medicament A, can be used for a single-medicament implementation of the infusion system that infuses only medicament B. In some embodiments, asymmetric features in the dual-medicament infusion site connectors, such as any combination of asymmetric posts, asymmetric post receptacles, retention clips, alignment posts, and/or keys and keyways can be used to differentiate the single-medicament infusion site connector for medicament A from medicament B. In some embodiments, such features can also be used to ensure that a single-medicament implementation of the infusion system that infuses only medicament A uses only the medicament A chamber in the pump housing, and a single-medicament implementation of the infusion system that infuses only medicament B uses only the medicament B chamber in the pump housing. In some embodiments, in this way, the same molds used to manufacture the dual-medicament infusion site connectors will serve for the single-medicament infusion site connectors for a single-medicament implementation of the infusion system that infuses only medicament A or only medicament B. Thus, the constituent components of the dual-medicament infusion site base, dual-medicament infusion site connectors, tubing, and needle connectors, which serve a dual-medicament implementation of the infusion system, can be used to serve one of two distinct single-medicament implementations of the infusion system, one for medicament A and one for medicament B.
In some embodiments, software (either integrated into the infusion system or run on an auxiliary device such as a smart-phone or tablet) can be used to configure (automatically and/or manually) the infusion system to be configured either as a dual-medicament infusion system, as a single-medicament infusion system that uses only the medicament A chamber in the pump housing, or a single-medicament infusion system that uses only the medicament B chamber in the pump housing. In some embodiments, once any of these three configurations is implemented, the dual-medicament infusion site connectors or appropriate single-medicament infusion site connectors (either pertaining to medicament A or medicament B) can be chosen to match the particular configuration.
In some embodiments involving a site connector or site connectors, each site connector can be designed to connect to a site base by the action of at least one retention clip. Connection of a site connector to a site base allows a straight, beveled, hollow, stainless steel needle to pierce a septum in the site base (as in
In some embodiments involving the use of a site base, the 90 degree, beveled, hollow, stainless steel needle can be overmolded, bonded, press-fitted, glued, solvent bonded, insert molded, or otherwise attached to the site base. In some embodiments, as an example other than insert molding, such a 90-degree, beveled, hollow, stainless steel needle may be sheathed with a soft durometer tube, which is in turn press-fit into the site base septum to create a sub-assembly outside the site base. In some embodiments, this sub-assembly can then be placed into a cavity in the site base (as shown in
In some embodiments involving the use of a site base, the 90 degree, beveled, hollow, stainless steel needle, the needle may be designed to protrude from the center or near the center of the site base. In some embodiments, this arrangement increases the likelihood that the site base will remain adhered to the surface of the skin for the entirety of its intended use.
In some embodiments involving multiple medicaments where a site connector can be connected to or disconnected from a site base, the site connectors and site bases can contain features such as lettering or other visual indicators to help prevent mis-connection of a site base or a site connector to incorrect site connectors or site bases. In some embodiments, such lettering or other visual indicators (colors, etc.) can be used in addition to physical features that mechanically prevent mis-connection. In some embodiments, the lettering or other visual indicators can be raised and colored differently from the base material to enhance visibility.
In some embodiments involving multiple medicaments where a site connector can be connected to or disconnected from a site base, the site connectors and the site bases can contain features such as asymmetric post receptacles, retention clips, alignment posts, and/or keys and keyways that prevent mis-connection of a site base or a site connector to incorrect site connectors or site bases.
In some embodiments involving a site connector or site connectors, each site connector can be designed to connect to a site base by the action of at least one retention clip that fits into at least one retention slot. In some embodiments involving two medicaments where only one retention clip and retention slot pair is used on each site connector and site base pair, the retention clips and retention slots may be present on the medial or lateral (as in
In some embodiments involving two medicaments, a right site connector and a left site connector (as in
In some embodiments involving two medicaments, a right (first) site base and a left (second) site base (as in
In some embodiments the site connectors and site bases are designed such that any site connector and site base pair from a multiple medicament configuration can be used individually in a single medicament configuration (as in
In some embodiments involving multiple medicaments, the site connectors can be supplied with one or more site connector covers that may couple all of the site connectors, certain groups of the site connectors, or none of the site connectors such that each site connector can be supplied with its own site connector cover. The site connector cover can be connected to and disconnected from the site connectors repeatedly and protects them from exposure (as in
In some embodiments involving a single medicament or multiple medicaments wherein each site base is supplied with its own site base cover and each site connector is supplied with its own site connector cover, the site base covers and the site connector covers could be manufactured from the same tools as the site bases and the site connectors respectively. In some embodiments, each site base cover may not contain the straight, beveled, hollow, stainless steel needle and the tubing and each site connector cover may not contain the 90 degree, beveled, hollow, stainless steel needle and the site base septum.
In some embodiments involving a single medicament or multiple medicaments, the site base or site bases can be supplied with a site base inserter that connects to the site base or site bases in the same manner as the site connectors and provides a handle for the application of site base or site bases (as in
In some embodiments, the infusion pump may be equipped with a cartridge detection hardware-software system that would detect, separately, whenever each cartridge is fully loaded and secured in its corresponding pump chamber. In some embodiments, since the design described herein can ensure that only the correct medicament cartridge can be fully loaded and secured in its corresponding pump chamber, the cartridge detection system can, when functioning in conjunction with the design described herein, effectively and conclusively inform the infusion pump system of which specific medicaments are available for potential infusion. In some embodiments, the availability status of each medicament for potential infusion at any point in time would also allow the infusion pump system to set its mode of operation accordingly. In some embodiments, for example, in the case of a dual-chamber pump, the detection of both cartridges being in place would allow the infusion pump system to operate in dual-infusion mode, whereas the detection of one cartridge being in place but not the other would lead the infusion pump system to operate in a single-infusion mode that is specific to the medicament that corresponds to the cartridge that is detected to be in place. In some embodiments, this detection capability would be determined autonomously in real time, including when a cartridge is in place or out of place transiently or temporarily.
In some embodiments, the infusion pump may also be equipped with a delivery occlusion hardware-software detection system that would detect, separately, whenever the fluid-delivery path associated with each cartridge is impeded or obstructed anywhere from the cartridge, all the way through the corresponding tubing, and out to the distal end of the corresponding site base. In some embodiments, since the design described herein can ensure that only the correct tubing assembly and site base can be connected to their corresponding cartridge, the occlusion detection system would, when functioning in conjunction with the design described herein, effectively and conclusively inform the infusion pump system of which specific medicaments have a patent fluid-delivery path.
In some embodiments, with both cartridge and occlusion detection systems simultaneously present, the infusion pump may at any point in time conclusively determines which medicament is possible to deliver to the user. In some embodiments, the infusion pump could then autonomously set its mode of operation, as per the detection of which of the cartridges are in place along with the patency of their corresponding fluid-delivery paths. In some embodiments, in a specialized example of a dual-chamber pump that autonomously controls blood glucose levels by delivering insulin or an insulin analog, as well as a counter-regulatory agent (e.g. glucagon, a glucagon analog, or dextrose), such cartridge and occlusion detection systems, when functioning in conjunction with the design described here, would practically allow the infusion pump system to be prescribed in a particular configuration to deliver only insulin, or only the counter-regulatory agent, or both. Moreover, in some embodiments, such an implementation would also allow the dual-chamber infusion pump system to autonomously switch its mode of operation in real time whenever either delivery channel becomes unavailable for delivery (whether informed by cartridge detection, occlusion detection, or both), including in cases where channel availability may alternate in real time. In some embodiments, the cartridge and occlusion detection methods could be realized through a variety of hardware and software implementations, including, but not limited to, techniques that rely on magnetic field or electrical signal feedback in the case of cartridge detection, or techniques that rely on back pressure detection or flow sensor technology in the case of occlusion detection, to mention but a few.
In some embodiments, the features described in the context of one base, connector, housing, inlet connector, inlet connector cover, collar, medicament reservoir, or pump assembly can be mixed and matched and used in different combinations on other bases, connectors, housings, inlet connectors, inlet connector covers, collars, medicament reservoirs, or pump assemblies. For instance, any feature described above to prevent mischanneling can be deleted from or added to other embodiments. Redundant features can be added or deleted from the components of the medicament delivery systems.
The examples shown here are meant to be representative of a general approach to the design of an infusion system for multiple medicaments and various connectors, tubes, and cartridges to ensure proper channeling of each medicament to the patient. The geometric shapes, sizes, orientations, locations, and number of tabs, protrusions, and features, as well as the corresponding cavities, grooves, keyways, or slots are merely meant to be examples of a much greater abundance of variations on the particular examples shown here.
For instance, as described elsewhere herein, the degrees of separation between the tabs, protrusions, and features on the cap connectors and on the corresponding cavities, grooves, keyways, or slots in the pump housing, or the degrees of separation between the tabs, protrusions, and features on the pre-fitted collar assembly and the corresponding cavities, grooves, keyways, or slots on the cap connector shown here can be generalized to be placed closer together or farther apart than in the examples shown here. Additionally, the number of tabs, protrusions, and features on the cap connectors and on the corresponding cavities, grooves, keyways, or slots in the pump housing, or the number of tabs, protrusions, and features on the pre-fitted collar assembly and the corresponding cavities, grooves, keyways, or slots on the cap connector designs shown here can be generalized to one, two, three or more such features, which might have different sizes, shapes, orientations, and locations from the examples shown here. Moreover, as discussed above, the locations of the tabs, protrusions, and features on the pre-fitted collar assembly and the corresponding cavities, grooves, keyways, or slots on the cap connector designs shown here need not be limited to the neck or head (or crown) regions of the cartridge. For instance, the point of engagement between the pre-fitted collar assembly and the cap connector could alternatively occur elsewhere on the body of the cartridge, or extend over the entire length of the cartridge. In some embodiments, the tabs, protrusions, and features on the pre-fitted collar assemblies described here could instead appear directly on the surface of the cartridge (such as in the case of an injection molded cartridge), which is either pre-filled with medicament or not pre-filled with medicament.
In some embodiments, the cartridges described here can either be pre-filled with medicament or not pre-filled with medicament before or after the pre-fitted collar assemblies described here are installed onto the cartridge. In the case of the latter, such cartridges can be filled with medicament sometime after the manufacturing process, including at the point of care.
In some embodiments, for example in the case of a cartridge that is filled with medicament at the point of care, the cap connector might not contain a recessed needle, but rather might couple with said cartridge using a standard luer lock or other mechanism, as in
In some embodiments, mischanneling of medicaments can still be avoided if one cartridge is prefilled with one medicament and a second cartridge is filled at the point of care with a different medicament (using the embodiment described in
In some embodiments, the features and components described above are applicable to reusable injection pens (e.g., insulin pens, etc.). In some embodiments, each collar, cap, input connector, etc. could be applied to prevent incorrect dosing of drugs delivered by injection pens. For example, one unique cartridge, having a first set of unique features as described above could be used to deliver long-acting insulin to a patient via a mated injection pen. Another unique cartridge, with a second set of unique features as described above could be used to deliver fast-acting or ultra-rapid insulin analogs to a patient via a different mated injection pen. As a further example, these features can be used to differentiate between more and less concentrated insulin analogs (e.g. U100, U200, or U500 insulin analogs).
The medicament described above for any embodiment can include any suitable compound or drug for treating, regulating, controlling or addressing one or more conditions of the patient. While diabetes mellitus is a target, other conditions can be addressed as well (e.g., pancreatic misfunction). The medicament can include for example a regulating agent, such as insulin, for regulating the blood glucose levels in the patient and/or a counter-regulatory agent, such as glucose or glucagon, for more effective blood glucose regulation in certain circumstances. Other type of agents can be used as well.
In some embodiments, an infusion system for multiple medicaments involving various needle sites, connectors, tubes, and cartridges that ensure proper channeling of each medicament to the patient is provided. In some embodiments, the infusion system comprises an infusion pump. In some embodiments, the infusion system comprises an infusion pump with two or more pump chambers. In some embodiments, the infusion system comprises cartridges that can be filled at the point of care with different medicaments (or may be pre-filled with different medicaments). In some embodiments, the infusion system comprises connectors and tubing that connect the cartridges to the infusion pump in such a way as to prevent mischanneling or cross-channeling of medicaments. In some embodiments, each type of cartridge for each type of medicament has unique differentiating sizes, shapes, and/or geometrical features (either as an integral part of the cartridge or as a component attached or affixed to the cartridge) that allow for unique coupling with a type of connector that itself has unique differentiating features that engage corresponding features in the pump housing and only allow for insertion of the proper cartridge into the proper pump chamber within the infusion pump.
In some embodiments, the systems described above can be used for the delivery of single medicaments, or combinations of medicaments. For instance, in some embodiments, the infusion set can be used to deliver agent A (e.g., insulin), while the features of that infusion set would be incompatible with the medicament reservoir for agent B (e.g., glucagon). Alternatively, in some embodiments, the infusion set can be used to deliver agent B, while the features of that infusion set would be incompatible with the medicament reservoir for agent A. Additionally, in some embodiments, as described above, dual medicaments can be delivered without mischanneling (e.g., bi-hormonal delivery, dual drug delivery, etc.). As is apparent from the disclosure above, configurations for the delivery of a plurality of medicaments (e.g., two, three, four, or more) without mischanneling can be provided.
In some embodiments, methods of making the infusion systems disclosed herein are provided. In some embodiments, various needle sites, connectors, tubes, and cartridges that ensure proper channeling of each medicament to the patient are assembled. In some embodiments, the method comprises assembling an infusion system with an infusion pump. In some embodiments, the method comprises assembling an infusion system with a pump having two or more pump chambers. In some embodiments, the method comprises assembling an infusion system with connectors and tubing that connect the cartridges to the infusion pump in such a way as to prevent mischanneling or cross-channeling of medicaments. In some embodiments, each type of cartridge for each type of medicament is assembled to have unique differentiating sizes, shapes, and/or geometrical features (either as an integral part of the cartridge or as a component attached or affixed to the cartridge) that allow for unique coupling with a type of connector that itself has unique differentiating features that engage corresponding features in the pump housing and only allow for insertion of the proper cartridge into the proper pump chamber within the infusion pump.
In some embodiments, the pump can include a controller. In some embodiments, the controller includes a memory and one or more hardware processors. The memory can include a non-transitory, computer-readable medium capable of storing computer-executable instructions for the pump or infusion system. The executable instructions can correspond to the processes and functions described above. For example, the executable instructions can correspond to the detection sequence described above and/or other processes such as reading optical codes, operating valves, and/or providing indications as described elsewhere herein. In some embodiments, the executable instructions also include instructions for controlling hardware components of the pump, for example, the motor, scanners, etc. The executable instructions can be implemented in C, C++, JAVA, or any other suitable programming languages. In some embodiments, the controller can include electronic circuits, for example, application specific circuitry such as ASICs and FPGAs, where some or all of the portions of the executable instructions can be implemented using the electronic circuits.
In certain embodiments, the computer-readable medium storing computer-executable instructions, when executed by one or more hardware processors, cause the one or more hardware processors to perform one or more of the following: urge the drive nut forward with force that is insufficient to move a plunger of an medicament reservoir, detect when the drive nut has contacted the plunger, determine if the plunger is that of an appropriately or inappropriately placed medicament, increase the force applied to the drive nut to deliver the medicament where the medicament reservoir is appropriate to deliver the medicament, or decrease the force applied to the drive nut and/or stop and/or retract the drive nut where the medicament reservoir is inappropriately placed in the pump.
In certain embodiments, the computer-readable medium storing computer-executable instructions, when executed by one or more hardware processors, cause the one or more hardware processors to perform one or more of the following: receive information concerning the medicament reservoir that is present in the pump, compare the medicament reservoir to medicament settings on the pump assembly, indicate a deviation from or proximity to the medicament settings based at least in part on a comparison of the settings required for the medicament reservoir and the settings on the pump, and/or adjust the settings of the pump to match appropriate medicament settings based on the medicament reservoir that is present.
One or more of the settings of the infusion assembly or other information as described elsewhere herein can be stored as one or more executable program modules in the memory of the controller and/or on other types of non-transitory computer-readable storage media, and the system can interact with computing assets over a network or other communication link. In some embodiments, the system may have additional components or fewer components than described above. For example, the controller of the pump can communicate to a server or another computing device over the network.
Depending on the embodiment, certain acts, events, or functions of any of the processes or algorithms described herein can be performed in a different sequence, can be added, merged, or left out altogether (e.g., not all described operations or events are necessary for the practice of the algorithm). Moreover, in certain embodiments, operations or events can be performed concurrently, e.g., through multi-threaded processing, interrupt processing, or multiple processors or processor cores or on other parallel architectures, rather than sequentially.
The various illustrative logical blocks, modules, routines, and algorithm steps described in connection with the embodiments disclosed herein can be implemented as electronic hardware, or as a combination of electronic hardware and executable software as discussed above with respect to controller.
This application is a continuation of U.S. application Ser. No. 16/503,269, filed Jul. 3, 2019, which is a continuation of PCT Application Serial No. PCT/US2018/012636, filed Jan. 5, 2018, which claims priority to U.S. Provisional Patent Application No. 62/444,244, filed Jan. 9, 2017 and U.S. Provisional Patent Application No. 62/443,616, filed Jan. 6, 2017. All of the foregoing applications are hereby incorporated herein by reference in their entireties. Any and all applications for which a priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 C.F.R. § 1.57.
This invention was made with Government Support under Contract Nos. DK097657 and DK108612 awarded by the National Institutes of Health. The Government has certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1930929 | Eisenberg | Oct 1933 | A |
| 3807467 | Tascher et al. | Apr 1974 | A |
| 4150673 | Watt | Apr 1979 | A |
| 4253501 | Ogle | Mar 1981 | A |
| 4515584 | Abe et al. | May 1985 | A |
| 4585439 | Michel | Apr 1986 | A |
| 4608042 | Vanderveen et al. | Aug 1986 | A |
| 4675006 | Hrushesky | Jun 1987 | A |
| 5085643 | Larkin et al. | Feb 1992 | A |
| 5243982 | Mostl | Sep 1993 | A |
| 5298023 | Haber | Mar 1994 | A |
| 5356380 | Hoekwater et al. | Oct 1994 | A |
| 5411480 | Kriesel | May 1995 | A |
| 5472403 | Cornacchia | Dec 1995 | A |
| 5505704 | Pawelka et al. | Apr 1996 | A |
| 5522803 | Teissen-Simony | Jun 1996 | A |
| 5545152 | Funderburk et al. | Aug 1996 | A |
| 5616124 | Hague et al. | Apr 1997 | A |
| 5916494 | Widman et al. | Jun 1999 | A |
| 5954697 | Srisathapat et al. | Sep 1999 | A |
| 5961494 | Hogan | Oct 1999 | A |
| 5971972 | Rosenbaum | Oct 1999 | A |
| 6106498 | Friedli et al. | Aug 2000 | A |
| 6132416 | Broselow | Oct 2000 | A |
| 6248067 | Causey, III et al. | Jun 2001 | B1 |
| 6259587 | Sheldon et al. | Jul 2001 | B1 |
| 6360784 | Philippens et al. | Mar 2002 | B1 |
| 6362591 | Moberg | Mar 2002 | B1 |
| 6368314 | Kipfer et al. | Apr 2002 | B1 |
| 6390130 | Guala | May 2002 | B1 |
| 6485465 | Moberg et al. | Nov 2002 | B2 |
| 6551276 | Mann et al. | Apr 2003 | B1 |
| 6551298 | Zhang et al. | Apr 2003 | B1 |
| 6554798 | Mann et al. | Apr 2003 | B1 |
| 6555986 | Moberg | Apr 2003 | B2 |
| 6558320 | Causey, III et al. | May 2003 | B1 |
| 6572545 | Knobbe et al. | Jun 2003 | B2 |
| 6585695 | Adair et al. | Jul 2003 | B1 |
| 6620138 | Marrgi et al. | Sep 2003 | B1 |
| 6641533 | Causey, III et al. | Nov 2003 | B2 |
| 6652483 | Slate | Nov 2003 | B2 |
| 6656148 | Das et al. | Dec 2003 | B2 |
| 6659980 | Moberg et al. | Dec 2003 | B2 |
| 6719728 | Mason et al. | Apr 2004 | B2 |
| 6736797 | Larsen et al. | May 2004 | B1 |
| 6752787 | Causey, III et al. | Jun 2004 | B1 |
| 6801420 | Talbot et al. | Oct 2004 | B2 |
| 6809653 | Mann et al. | Oct 2004 | B1 |
| 6811534 | Bowman et al. | Nov 2004 | B2 |
| 6821421 | Murakami | Nov 2004 | B2 |
| 6854620 | Ramey | Feb 2005 | B2 |
| 6872200 | Mann et al. | Mar 2005 | B2 |
| 6878132 | Kipfer | Apr 2005 | B2 |
| 6936029 | Mann et al. | Aug 2005 | B2 |
| 6939329 | Verkaart | Sep 2005 | B1 |
| 6958705 | Lebel et al. | Oct 2005 | B2 |
| 6960198 | Sarmiento | Nov 2005 | B2 |
| 6979326 | Mann et al. | Dec 2005 | B2 |
| 6997920 | Mann et al. | Feb 2006 | B2 |
| 7025226 | Ramey | Apr 2006 | B2 |
| 7025743 | Mann et al. | Apr 2006 | B2 |
| 7098803 | Mann et al. | Aug 2006 | B2 |
| 7109878 | Mann et al. | Sep 2006 | B2 |
| 7187528 | Talbot et al. | Mar 2007 | B2 |
| 7193521 | Moberg et al. | Mar 2007 | B2 |
| 7281314 | Hess et al. | Oct 2007 | B2 |
| 7285105 | Kim et al. | Oct 2007 | B2 |
| 7291133 | Kindler et al. | Nov 2007 | B1 |
| 7324012 | Mann et al. | Jan 2008 | B2 |
| 7342508 | Morgan et al. | Mar 2008 | B2 |
| 7460350 | Talbot et al. | Dec 2008 | B2 |
| 7534226 | Mernoe et al. | May 2009 | B2 |
| 7602310 | Mann et al. | Oct 2009 | B2 |
| 7621893 | Moberg et al. | Nov 2009 | B2 |
| 7625354 | Hochman | Dec 2009 | B2 |
| 7628772 | McConnell et al. | Dec 2009 | B2 |
| 7628782 | Adair et al. | Dec 2009 | B2 |
| 7648494 | Kornerup et al. | Jan 2010 | B2 |
| 7654127 | Krulevitch et al. | Feb 2010 | B2 |
| 7655618 | Green et al. | Feb 2010 | B2 |
| 7658734 | Adair et al. | Feb 2010 | B2 |
| 7678762 | Green et al. | Mar 2010 | B2 |
| 7678763 | Green et al. | Mar 2010 | B2 |
| 7683027 | Green et al. | Mar 2010 | B2 |
| 7708717 | Estes et al. | May 2010 | B2 |
| 7760481 | Talbot et al. | Jul 2010 | B2 |
| 7766873 | Moberg et al. | Aug 2010 | B2 |
| 7776030 | Estes et al. | Aug 2010 | B2 |
| 7789859 | Estes et al. | Sep 2010 | B2 |
| 7794427 | Estes et al. | Sep 2010 | B2 |
| 7794428 | Estes et al. | Sep 2010 | B2 |
| 7815602 | Mann et al. | Oct 2010 | B2 |
| 7819843 | Mann et al. | Oct 2010 | B2 |
| 7831310 | Lebel et al. | Nov 2010 | B2 |
| 7833196 | Estes et al. | Nov 2010 | B2 |
| 7879010 | Hunn et al. | Feb 2011 | B2 |
| 7879026 | Estes et al. | Feb 2011 | B2 |
| 7887512 | Estes et al. | Feb 2011 | B2 |
| 7892206 | Moberg et al. | Feb 2011 | B2 |
| 7914449 | Kouchi et al. | Mar 2011 | B2 |
| 7922708 | Estes et al. | Apr 2011 | B2 |
| 7951112 | Patzer | May 2011 | B2 |
| 7967785 | Morgan et al. | Jun 2011 | B2 |
| 7981084 | Estes et al. | Jul 2011 | B2 |
| 7981105 | Adair et al. | Jul 2011 | B2 |
| 7988683 | Adair et al. | Aug 2011 | B2 |
| 7998111 | Moberg et al. | Aug 2011 | B2 |
| 7998131 | Adair et al. | Aug 2011 | B2 |
| 8004422 | Hess et al. | Aug 2011 | B2 |
| 7938803 | Mernoe et al. | Oct 2011 | B2 |
| 8034026 | Grant et al. | Oct 2011 | B2 |
| 8057436 | Causey et al. | Nov 2011 | B2 |
| 8062257 | Moberg et al. | Nov 2011 | B2 |
| 8065096 | Moberg et al. | Nov 2011 | B2 |
| 8088096 | Lauchard et al. | Jan 2012 | B2 |
| 8105279 | Mernoe et al. | Jan 2012 | B2 |
| 8106534 | Spurlin et al. | Jan 2012 | B2 |
| 8142397 | Patzer | Mar 2012 | B2 |
| 8167846 | Chong et al. | May 2012 | B2 |
| 8177767 | Kristensen et al. | May 2012 | B2 |
| 8182447 | Moberg et al. | May 2012 | B2 |
| 8192394 | Estes et al. | Jun 2012 | B2 |
| 8197444 | Bazargan et al. | Jun 2012 | B1 |
| 8206350 | Mann et al. | Jun 2012 | B2 |
| 8206353 | Chong et al. | Jun 2012 | B2 |
| 8211059 | Kriesel et al. | Jul 2012 | B2 |
| 8211062 | Estes et al. | Jul 2012 | B2 |
| 8251959 | Johner et al. | Aug 2012 | B2 |
| 8257345 | Adair et al. | Sep 2012 | B2 |
| 8267893 | Moberg et al. | Sep 2012 | B2 |
| 8273061 | McConnell et al. | Sep 2012 | B2 |
| 8282601 | Mernoe et al. | Oct 2012 | B2 |
| 8287495 | Michaud et al. | Oct 2012 | B2 |
| 8287516 | Kornerup et al. | Oct 2012 | B2 |
| 8298184 | Diperna et al. | Oct 2012 | B2 |
| 8303572 | Adair et al. | Nov 2012 | B2 |
| 8372039 | Mernoe et al. | Feb 2013 | B2 |
| 8409142 | Causey et al. | Apr 2013 | B2 |
| 8430847 | Mernoe et al. | Apr 2013 | B2 |
| 8430849 | Smith et al. | Apr 2013 | B2 |
| 8454575 | Estes et al. | Jun 2013 | B2 |
| 8469942 | Kow et al. | Jun 2013 | B2 |
| 8475408 | Mernoe et al. | Jul 2013 | B2 |
| 8480623 | Mernoe et al. | Jul 2013 | B2 |
| 8483980 | Moberg et al. | Jul 2013 | B2 |
| 8500716 | Adair et al. | Aug 2013 | B2 |
| 8512276 | Talbot et al. | Aug 2013 | B2 |
| 8512289 | Chong et al. | Aug 2013 | B2 |
| 8523803 | Favreau | Sep 2013 | B1 |
| 8551045 | Sie et al. | Oct 2013 | B2 |
| 8551046 | Causey et al. | Oct 2013 | B2 |
| 8556856 | Bazargan et al. | Oct 2013 | B2 |
| 8556866 | Krulevitch et al. | Oct 2013 | B2 |
| 8562565 | Fonacier et al. | Oct 2013 | B2 |
| 8562587 | Kovatchev et al. | Oct 2013 | B2 |
| 8568349 | Shergold | Oct 2013 | B2 |
| 8573027 | Rosinko et al. | Nov 2013 | B2 |
| 8579813 | Causey, III et al. | Nov 2013 | B2 |
| 8597269 | Chong et al. | Dec 2013 | B2 |
| 8603026 | Favreau | Dec 2013 | B2 |
| 8603027 | Favreau | Dec 2013 | B2 |
| 8603033 | Bazargan et al. | Dec 2013 | B2 |
| 8613726 | Causey, III et al. | Dec 2013 | B2 |
| 8613731 | Hansen et al. | Dec 2013 | B2 |
| 8617110 | Moberg et al. | Dec 2013 | B2 |
| 8622966 | Causey, III et al. | Jan 2014 | B2 |
| 8628510 | Bazargan et al. | Jan 2014 | B2 |
| 8641671 | Michaud et al. | Feb 2014 | B2 |
| 8647074 | Moberg et al. | Feb 2014 | B2 |
| 8647296 | Moberg et al. | Feb 2014 | B2 |
| 8663103 | Causey, III et al. | Mar 2014 | B2 |
| 8674288 | Hanson et al. | Mar 2014 | B2 |
| 8679060 | Mernoe et al. | Mar 2014 | B2 |
| 8681010 | Moberg et al. | Mar 2014 | B2 |
| 8696633 | Estes et al. | Apr 2014 | B2 |
| 8747368 | Mernoe et al. | Jun 2014 | B2 |
| 8747369 | Mernoe et al. | Jun 2014 | B2 |
| 8758323 | Michaud et al. | Jun 2014 | B2 |
| 8771229 | Amirouche et al. | Jul 2014 | B2 |
| 8777901 | Smith et al. | Jul 2014 | B2 |
| 8790307 | Amirouche et al. | Jul 2014 | B2 |
| 8821442 | Haaar | Sep 2014 | B2 |
| 8823528 | Blomquist | Sep 2014 | B2 |
| 8834420 | Estes et al. | Sep 2014 | B2 |
| 8841012 | Fonacier et al. | Sep 2014 | B2 |
| 8864726 | Halili et al. | Oct 2014 | B2 |
| 8864737 | Hasegawa et al. | Oct 2014 | B2 |
| 8864739 | Moberg et al. | Oct 2014 | B2 |
| 8870829 | Halili et al. | Oct 2014 | B2 |
| 8876770 | Kraft et al. | Nov 2014 | B2 |
| 8900206 | Halili et al. | Dec 2014 | B2 |
| 8905972 | Smith et al. | Dec 2014 | B2 |
| 8915879 | Smith et al. | Dec 2014 | B2 |
| 8936573 | Blomquist | Jan 2015 | B2 |
| 8945068 | Halili et al. | Feb 2015 | B2 |
| 8974435 | Friedli | Mar 2015 | B2 |
| 8992475 | Mann et al. | Mar 2015 | B2 |
| 8992507 | Aeschlimann et al. | Mar 2015 | B2 |
| 8998840 | Hanson et al. | Apr 2015 | B2 |
| 8998842 | Lauchard et al. | Apr 2015 | B2 |
| 8998858 | Chong et al. | Apr 2015 | B2 |
| 9011371 | Moberg et al. | Apr 2015 | B2 |
| 9033925 | Moberg et al. | May 2015 | B2 |
| 9033951 | Kow et al. | May 2015 | B2 |
| 9050406 | Kow et al. | Jun 2015 | B2 |
| 9101710 | Yavorsky et al. | Aug 2015 | B2 |
| 9101715 | Causey, III et al. | Aug 2015 | B2 |
| 9107999 | Moberg et al. | Aug 2015 | B2 |
| 9114209 | Estes et al. | Aug 2015 | B2 |
| 9114213 | Murakami et al. | Aug 2015 | B2 |
| 9119917 | Blomquist | Sep 2015 | B2 |
| 9132228 | Yan | Sep 2015 | B2 |
| 9173998 | Rosinko et al. | Nov 2015 | B2 |
| 9180242 | Metzmaker et al. | Nov 2015 | B2 |
| 9180243 | Michaud | Nov 2015 | B2 |
| 9180254 | Avery et al. | Nov 2015 | B2 |
| 9184490 | Crouther et al. | Nov 2015 | B2 |
| 9194388 | Laermer | Nov 2015 | B2 |
| 9205192 | Estes et al. | Dec 2015 | B2 |
| 9211376 | Kouyoumjian et al. | Dec 2015 | B2 |
| 9211377 | Diperna et al. | Dec 2015 | B2 |
| 9216249 | Smith et al. | Dec 2015 | B2 |
| 9220835 | Cane' | Dec 2015 | B2 |
| 9250106 | Rosinko et al. | Feb 2016 | B2 |
| 9272009 | Spencer | Mar 2016 | B2 |
| 9283318 | Yavorsky et al. | Mar 2016 | B2 |
| 9295826 | Bertrand et al. | Mar 2016 | B2 |
| 9308320 | Smith et al. | Apr 2016 | B2 |
| 9308321 | Alderete et al. | Apr 2016 | B2 |
| 9314569 | Causey et al. | Apr 2016 | B2 |
| 9320849 | Smith et al. | Apr 2016 | B2 |
| 9327073 | Moberg et al. | May 2016 | B2 |
| 9335910 | Farnan et al. | May 2016 | B2 |
| 9339639 | Halili et al. | May 2016 | B2 |
| 9344024 | Favreau | May 2016 | B2 |
| 9345643 | Okiyama | May 2016 | B2 |
| 9364608 | Moberg et al. | Jun 2016 | B2 |
| 9379652 | Favreau | Jun 2016 | B2 |
| 9379653 | Favreau | Jun 2016 | B2 |
| 9381297 | Brown et al. | Jul 2016 | B2 |
| 9381300 | Smith et al. | Jul 2016 | B2 |
| 9393399 | Yavorsky et al. | Jul 2016 | B2 |
| 9415157 | Mann et al. | Aug 2016 | B2 |
| 9427519 | Kraft et al. | Aug 2016 | B2 |
| 9433731 | Track et al. | Sep 2016 | B2 |
| 9433732 | Moberg et al. | Sep 2016 | B2 |
| 9433733 | Moberg et al. | Sep 2016 | B2 |
| 9452255 | Tieck et al. | Sep 2016 | B2 |
| 9452256 | Tieck et al. | Sep 2016 | B2 |
| 9463309 | Yavorsky et al. | Oct 2016 | B2 |
| 9494147 | Chong et al. | Nov 2016 | B2 |
| 9498573 | Smith et al. | Nov 2016 | B2 |
| 9514518 | Gillespie et al. | Dec 2016 | B2 |
| 9517299 | Tieck et al. | Dec 2016 | B2 |
| 9517301 | Estes et al. | Dec 2016 | B2 |
| 9533132 | Halili et al. | Jan 2017 | B2 |
| 9539385 | Mathys | Jan 2017 | B2 |
| 9539388 | Causey et al. | Jan 2017 | B2 |
| 9554967 | Moia et al. | Jan 2017 | B2 |
| 9579452 | Adair et al. | Feb 2017 | B2 |
| 9592339 | Zhou | Mar 2017 | B2 |
| 9597462 | Moore | Mar 2017 | B2 |
| 9610431 | Halili et al. | Apr 2017 | B2 |
| 9629992 | Halili et al. | Apr 2017 | B2 |
| 9636453 | Monirabbasi et al. | May 2017 | B2 |
| 9682189 | Good et al. | Jun 2017 | B2 |
| 9687612 | Avery et al. | Jun 2017 | B2 |
| 9715327 | Rosinko et al. | Jul 2017 | B2 |
| 9717845 | Istoc | Aug 2017 | B2 |
| 9717848 | Geismar et al. | Aug 2017 | B2 |
| 9731067 | Pananen | Aug 2017 | B2 |
| 9744290 | Tieck et al. | Aug 2017 | B2 |
| 9744291 | Tieck et al. | Aug 2017 | B2 |
| 9744301 | Mann et al. | Aug 2017 | B2 |
| 9750871 | Metzmaker et al. | Sep 2017 | B2 |
| 9750873 | Brown et al. | Sep 2017 | B2 |
| 9750875 | Smith et al. | Sep 2017 | B2 |
| 9770553 | Bazargan et al. | Sep 2017 | B2 |
| 9782543 | Groeschke et al. | Oct 2017 | B2 |
| 9789245 | Tieck et al. | Oct 2017 | B2 |
| 9795732 | Trock et al. | Oct 2017 | B2 |
| 9801787 | Py | Oct 2017 | B2 |
| 9814830 | Mernoe et al. | Nov 2017 | B2 |
| 9814872 | Eggert et al. | Nov 2017 | B2 |
| 9839741 | Yavorsky et al. | Dec 2017 | B2 |
| 9841014 | Yap et al. | Dec 2017 | B2 |
| 9863837 | Rule et al. | Jan 2018 | B2 |
| 9872957 | Causey et al. | Jan 2018 | B2 |
| 9883834 | Amirouche et al. | Feb 2018 | B2 |
| 9889256 | Cabiri et al. | Feb 2018 | B2 |
| 9895490 | Kow et al. | Feb 2018 | B2 |
| 9925330 | Tieck et al. | Mar 2018 | B2 |
| 9931459 | Tieck et al. | Apr 2018 | B2 |
| 9931460 | Tieck et al. | Apr 2018 | B2 |
| 9943645 | Monirabbasi et al. | Apr 2018 | B2 |
| 9950113 | Franke et al. | Apr 2018 | B2 |
| 9987420 | Pananen | Jun 2018 | B2 |
| 9993592 | Amirouche et al. | Jun 2018 | B2 |
| 9993594 | Bazargan et al. | Jun 2018 | B2 |
| 10010674 | Rosinko et al. | Jul 2018 | B2 |
| 10010678 | Schildt et al. | Jul 2018 | B2 |
| 10016564 | Piehl et al. | Jul 2018 | B2 |
| 10029045 | Smith et al. | Jul 2018 | B2 |
| 10064993 | Mernoe et al. | Sep 2018 | B2 |
| 10071200 | Alderete et al. | Sep 2018 | B2 |
| 10080839 | Cole et al. | Sep 2018 | B2 |
| 10086133 | Pananen et al. | Oct 2018 | B2 |
| 10086134 | Pananen et al. | Oct 2018 | B2 |
| 10092701 | Johansen et al. | Oct 2018 | B2 |
| 10105483 | Mernoe | Oct 2018 | B2 |
| 10105497 | Dreier et al. | Oct 2018 | B2 |
| 10130759 | Amirouche et al. | Nov 2018 | B2 |
| 10130763 | Lauchard et al. | Nov 2018 | B2 |
| 10137243 | Wang et al. | Nov 2018 | B2 |
| 10141882 | Favreau | Nov 2018 | B2 |
| 10146911 | Trock | Dec 2018 | B2 |
| 10166327 | Tieck et al. | Jan 2019 | B2 |
| 10172998 | Tieck et al. | Jan 2019 | B2 |
| 10172999 | Tieck et al. | Jan 2019 | B2 |
| 10207047 | Estes | Feb 2019 | B2 |
| 10213549 | Amirouche et al. | Feb 2019 | B2 |
| 10220143 | Moberg et al. | Mar 2019 | B2 |
| 10228663 | Favreau | Mar 2019 | B2 |
| 10232109 | Deak et al. | Mar 2019 | B2 |
| 10238030 | Urbani | Mar 2019 | B2 |
| 10238793 | Deak et al. | Mar 2019 | B2 |
| 10252001 | Geismar et al. | Apr 2019 | B2 |
| 10258736 | Metzmaker et al. | Apr 2019 | B2 |
| 10272196 | Smith et al. | Apr 2019 | B2 |
| 10279110 | Mann et al. | May 2019 | B2 |
| 10300264 | Halili et al. | May 2019 | B2 |
| 10307536 | Causey et al. | Jun 2019 | B2 |
| 10322227 | Piehl et al. | Jun 2019 | B2 |
| 10363365 | Bazargan | Jul 2019 | B2 |
| 10376631 | Tieck et al. | Aug 2019 | B2 |
| 10376632 | Tieck et al. | Aug 2019 | B2 |
| 10384013 | Krusell et al. | Aug 2019 | B2 |
| 10391257 | Piehl et al. | Aug 2019 | B2 |
| 10478554 | Bazargan et al. | Nov 2019 | B2 |
| 10517892 | Chattaraj et al. | Dec 2019 | B2 |
| 10532156 | Istoc | Jan 2020 | B2 |
| 10552580 | Bazargan | Feb 2020 | B2 |
| 10603431 | Mernoe et al. | Mar 2020 | B2 |
| 10772796 | Kavazov | Sep 2020 | B2 |
| 10850032 | Steck et al. | Dec 2020 | B2 |
| 10857287 | Damiano et al. | Dec 2020 | B2 |
| 10861591 | Grosman et al. | Dec 2020 | B2 |
| 10960136 | Palerm et al. | Mar 2021 | B2 |
| 20020019608 | Mason et al. | Feb 2002 | A1 |
| 20020038392 | De La Huerga | Mar 2002 | A1 |
| 20020055711 | Lavi et al. | May 2002 | A1 |
| 20020065484 | Douglas et al. | May 2002 | A1 |
| 20020161332 | Ramey | Oct 2002 | A1 |
| 20030009133 | Ramey | Jan 2003 | A1 |
| 20050015056 | Duchon et al. | Jan 2005 | A1 |
| 20050020980 | Inoue | Jan 2005 | A1 |
| 20050038387 | Kriesel | Feb 2005 | A1 |
| 20050051580 | Ramey | Mar 2005 | A1 |
| 20050154434 | Simon et al. | Jul 2005 | A1 |
| 20050215979 | Kornerup et al. | Sep 2005 | A1 |
| 20060102174 | Hochman | May 2006 | A1 |
| 20060264908 | Ishii et al. | Nov 2006 | A1 |
| 20070088271 | Richards | Apr 2007 | A1 |
| 20070142786 | Lampropoulos et al. | Jun 2007 | A1 |
| 20070161955 | Bynum et al. | Jul 2007 | A1 |
| 20070273671 | Zadesky et al. | Nov 2007 | A1 |
| 20070282294 | Sidler | Dec 2007 | A1 |
| 20080051719 | Nair et al. | Feb 2008 | A1 |
| 20080119792 | Kornerup et al. | May 2008 | A1 |
| 20080188813 | Miller et al. | Aug 2008 | A1 |
| 20080243085 | DeStefano | Oct 2008 | A1 |
| 20080262425 | Mogensen | Oct 2008 | A1 |
| 20080319383 | Byland | Dec 2008 | A1 |
| 20090099523 | Grant et al. | Apr 2009 | A1 |
| 20090281505 | Hansen et al. | Nov 2009 | A1 |
| 20090326506 | Hasegawa et al. | Dec 2009 | A1 |
| 20100004603 | Kristensen et al. | Jan 2010 | A1 |
| 20100049144 | McConnell et al. | Feb 2010 | A1 |
| 20100191165 | Appling et al. | Jul 2010 | A1 |
| 20100217241 | Mann et al. | Aug 2010 | A1 |
| 20110021905 | Patrick et al. | Jan 2011 | A1 |
| 20110118659 | Maaskamp | May 2011 | A1 |
| 20110230838 | Adams et al. | Sep 2011 | A1 |
| 20110288494 | Mendels | Nov 2011 | A1 |
| 20120078170 | Smith et al. | Mar 2012 | A1 |
| 20120078185 | Smith et al. | Mar 2012 | A1 |
| 20120078197 | O'Connor et al. | May 2012 | A1 |
| 20120211946 | Halili et al. | Aug 2012 | A1 |
| 20120211947 | Halili et al. | Aug 2012 | A1 |
| 20120215177 | Halili et al. | Aug 2012 | A1 |
| 20120215178 | Halili et al. | Aug 2012 | A1 |
| 20120215179 | Halili et al. | Aug 2012 | A1 |
| 20120215180 | Halili et al. | Aug 2012 | A1 |
| 20120215183 | Halili et al. | Aug 2012 | A1 |
| 20120226234 | Bazargan et al. | Sep 2012 | A1 |
| 20120323188 | Yavorsky et al. | Dec 2012 | A1 |
| 20130046252 | Yavorsky et al. | Feb 2013 | A1 |
| 20130046253 | Yavorsky et al. | Feb 2013 | A1 |
| 20130066281 | Yavorsky et al. | Mar 2013 | A1 |
| 20130085470 | O'Connor et al. | Apr 2013 | A1 |
| 20130090602 | Avery et al. | Apr 2013 | A1 |
| 20130116632 | Yavorsky et al. | May 2013 | A1 |
| 20130183170 | Laermer | Jul 2013 | A1 |
| 20130237947 | Amirouche et al. | Sep 2013 | A1 |
| 20130245604 | Kouyoumjian et al. | Sep 2013 | A1 |
| 20130274576 | Amirouche et al. | Oct 2013 | A1 |
| 20130345641 | German | Dec 2013 | A1 |
| 20140052079 | Eggert et al. | Feb 2014 | A1 |
| 20140194815 | Kouyoumjian et al. | Jul 2014 | A1 |
| 20140276563 | Cole et al. | Sep 2014 | A1 |
| 20140378912 | Halili et al. | Dec 2014 | A1 |
| 20140378913 | Halili et al. | Dec 2014 | A1 |
| 20150045735 | Halili et al. | Feb 2015 | A1 |
| 20150057615 | Mernoe et al. | Feb 2015 | A1 |
| 20150073384 | Limaye | Mar 2015 | A1 |
| 20150202375 | Schabbach et al. | Jul 2015 | A1 |
| 20150265826 | Dudley | Sep 2015 | A1 |
| 20150314063 | Nagar et al. | Nov 2015 | A1 |
| 20150357683 | Lohr | Dec 2015 | A1 |
| 20160015885 | Pananen et al. | Jan 2016 | A1 |
| 20160015886 | Pananen et al. | Jan 2016 | A1 |
| 20160015887 | Pananen et al. | Jan 2016 | A1 |
| 20160015911 | Bazargan et al. | Jan 2016 | A1 |
| 20160051760 | Krusell et al. | Feb 2016 | A1 |
| 20160058668 | Metzmaker et al. | Mar 2016 | A1 |
| 20160074587 | Searle et al. | Mar 2016 | A1 |
| 20160082182 | Gregory et al. | Mar 2016 | A1 |
| 20160089493 | Crouther et al. | Mar 2016 | A1 |
| 20160106919 | Hayter et al. | Apr 2016 | A1 |
| 20160151563 | Yavorsky et al. | Jun 2016 | A1 |
| 20160184519 | Blundred et al. | Jun 2016 | A1 |
| 20160023591 | Damiano et al. | Aug 2016 | A1 |
| 20160220754 | Shaanan et al. | Aug 2016 | A1 |
| 20160263324 | Shaanan et al. | Sep 2016 | A1 |
| 20160271322 | Ramey | Sep 2016 | A1 |
| 20160361494 | Jurg et al. | Dec 2016 | A1 |
| 20170056590 | Diperna et al. | Mar 2017 | A1 |
| 20170065768 | Moore | Mar 2017 | A1 |
| 20170182307 | Halili et al. | Jun 2017 | A1 |
| 20170189666 | Sealfon et al. | Jul 2017 | A1 |
| 20170192506 | Andersen et al. | Jul 2017 | A1 |
| 20170216523 | Neftel et al. | Aug 2017 | A1 |
| 20170232203 | Krusell | Aug 2017 | A1 |
| 20170235920 | Bauss et al. | Aug 2017 | A1 |
| 20170239422 | Kodgule et al. | Aug 2017 | A1 |
| 20170286638 | Searle et al. | Oct 2017 | A1 |
| 20170312454 | Chattaraj et al. | Nov 2017 | A1 |
| 20180036475 | Lin | Feb 2018 | A1 |
| 20180043104 | Mueller-Pathle | Feb 2018 | A1 |
| 20180043105 | Nazzaro et al. | Feb 2018 | A1 |
| 20180103897 | Amirouche | Apr 2018 | A1 |
| 20180104417 | Nessel et al. | Apr 2018 | A1 |
| 20180117248 | Cabiri et al. | Jun 2018 | A1 |
| 20180117296 | Damiano et al. | Jun 2018 | A1 |
| 20180207366 | Marcoz et al. | Jul 2018 | A1 |
| 20180228979 | Schildt et al. | Aug 2018 | A1 |
| 20180280624 | Bitton et al. | Oct 2018 | A1 |
| 20180311435 | Galasso | Nov 2018 | A1 |
| 20180318498 | Grant et al. | Nov 2018 | A1 |
| 20180318506 | Oakes et al. | Nov 2018 | A1 |
| 20180326164 | Bauss et al. | Nov 2018 | A1 |
| 20180353699 | Helmer et al. | Dec 2018 | A1 |
| 20190001060 | Gylleby et al. | Jan 2019 | A1 |
| 20190009032 | Hautaviita et al. | Jan 2019 | A1 |
| 20190015582 | Naftalovitz et al. | Jan 2019 | A1 |
| 20190030247 | Edwards et al. | Jan 2019 | A1 |
| 20190054251 | Pieronek et al. | Feb 2019 | A1 |
| 20190091460 | Yavorsky et al. | Mar 2019 | A1 |
| 20190134305 | Srinivasan et al. | May 2019 | A1 |
| 20190151559 | Byerly et al. | May 2019 | A1 |
| 20190167900 | Friedli et al. | Jun 2019 | A1 |
| 20190192762 | Metzmaker et al. | Jun 2019 | A1 |
| 20190209775 | Merchant | Jul 2019 | A1 |
| 20190217007 | Sasaki | Jul 2019 | A1 |
| 20190344009 | Damiano et al. | Nov 2019 | A1 |
| 20200330719 | Segal | Oct 2020 | A1 |
| 20210030949 | Damiano et al. | Feb 2021 | A1 |
| 20210030957 | Beckstein et al. | Feb 2021 | A1 |
| 20210093777 | Damiano et al. | Apr 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 106061528 | Oct 2016 | CN |
| 2678056 | Jan 2014 | EP |
| 3060276 | Aug 2016 | EP |
| 3060277 | Aug 2016 | EP |
| 3062841 | Sep 2016 | EP |
| 3150241 | Jun 2018 | EP |
| 3378516 | Sep 2018 | EP |
| 3319662 | Mar 2019 | EP |
| 2059776 | Apr 1981 | GB |
| 1230529 | Dec 2017 | HK |
| 1254602 | Jul 2019 | HK |
| 5930241 | Feb 1984 | JP |
| 2016538098 | Aug 2016 | JP |
| 2018525060 | Sep 2018 | JP |
| 2549310 | Apr 2015 | RU |
| WO 9964103 | Dec 1999 | WO |
| 03017915 | Mar 2003 | WO |
| WO 2004045704 | Jun 2004 | WO |
| 05000378 | Jan 2005 | WO |
| WO 2005004973 | Jan 2005 | WO |
| WO 2006054367 | May 2006 | WO |
| WO 2009069511 | Apr 2009 | WO |
| WO 2007086186 | May 2009 | WO |
| WO 2009060741 | May 2009 | WO |
| 11131778 | Oct 2011 | WO |
| WO 2012008285 | Jan 2012 | WO |
| WO 2012072555 | Jun 2012 | WO |
| WO 2012110474 | Aug 2012 | WO |
| WO 20120115911 | Aug 2012 | WO |
| 12146670 | Nov 2012 | WO |
| WO 2012160104 | Nov 2012 | WO |
| WO 2013161979 | Oct 2013 | WO |
| WO 2014104027 | Mar 2014 | WO |
| WO 2015061690 | Apr 2015 | WO |
| WO 2015061691 | Apr 2015 | WO |
| WO 2015061693 | Apr 2015 | WO |
| WO 2015155229 | Oct 2015 | WO |
| WO 2015166993 | Nov 2015 | WO |
| WO 2017007968 | Jan 2017 | WO |
| WO 2017199012 | Nov 2017 | WO |
| WO 2017217105 | Dec 2017 | WO |
| WO 2018129354 | Jul 2018 | WO |
| WO 2019021985 | Jan 2019 | WO |
| WO 2019046593 | Mar 2019 | WO |
| Entry |
|---|
| Boston University, Jan. 2014, Bionic Pancreas: Introducing the iLet 1294 1000, http://sites.bu.edu/bionicpacreas/introducing-the-ilet-1294-1000/, 3 pp. |
| Brown et al., Apr. 1, 2016, Introducing Beta Bionics: bringing the iLet bionic pancreas to market, https://diatribe.org/introducing-beta-bionics-bringing-ilet-bionic-pancreas-marekt, 3 pp. |
| Hoskins, Oct. 2, 2018, iLet “Bionic Pancreas” making progress with gen 4 device, Healthline, https″//www.healthline.com/diabetesmine/beta-bionics-ilet-update#1, 15 pp. |
| Idlebrook, Jul. 30, 2019, Beta Bionics secures funding for pivotal iLet bionic pancreas trials, https://t1dexchange.org/welcome-glu-users/articles/beta-bionics-secures-funding-for-pivotal-ilet-bionic-pancreas-trials, 4 pp. |
| Krugman, Aug. 25, 2018, iLet Bionic Pancreas Interface, sarakrugman.com/ilet-interface, 3 pp. |
| Sifferlin, Apr. 1, 2016, The bionic pancreas is getting closer to reality, time.com, https://time.com/4278068/bionic-pancreas-company, 5 pp. |
| International Search Report and Written Opinion in PCT/US18/12636 dated Mar. 12, 2018 (BUNIV.003WO) in 14 pages. |
| Ping One Touch Owner's Booklet, Dated Oct. 2014, (360 pages). |
| Kolind et al., “Preservation-free drug for insulin pumps,” Novo Nordisk Pharmaceutical company, Pump partner meeting ATTD 2020, WOP Technology Presentation, 26 pages. |
| Renesas Synergy™ Platform, “Capacitive Touch Hardware Design and Layout Guidelines for Synergy, RX200, and RX100.” R01AN3825EU0101 Rev.1.01, Jun. 14, 2017, pp. 1-18. |
| Number | Date | Country | |
|---|---|---|---|
| 20210106750 A1 | Apr 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62444244 | Jan 2017 | US | |
| 62443616 | Jan 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16503269 | Jul 2019 | US |
| Child | 17110497 | US | |
| Parent | PCT/US2018/012636 | Jan 2018 | US |
| Child | 16503269 | US |
